分類: ACN Newswire

重點摘要：· 根據第三方產業報告，隨著醫療服務提供者持續轉向價值導向及居家照護模式，美國遠端病患監測（RPM）市場目前規模已達 140 億美元，預計到 2030 年將成長至約 290 億美元，年複合成長率（CAGR）為 12.6%¹· 透過其醫療服務組織（MSO）基礎設施，於多家醫療機構啟動試點計畫，專注於慢性病管理（CCM）及遠距病患監測（RPM）· 迄今透過此試點基礎設施已產生逾1,500筆理賠，且擴展藍圖目標涵蓋更多醫療服務提供者· Wellgistics 藥局網絡擁有超過6,500家獨立藥局，具備支援患者參與及照護協調計畫的優勢· 參與的藥師預期將獲得新的臨床服務營收機會佛羅里達州坦帕市, 2026年5月13日 - (亞太商訊 via SeaPRwire.com) - 領先的醫療科技與藥品分銷公司 Wellgistics Health, Inc.（納斯達克代碼：WGRX）（以下簡稱「Wellgistics」或「本公司」）今日宣布，將與 Kare PharmTech 及 Kare Clinicals 展開試點合作，整合其醫療服務組織（MSO）基礎設施，以支援參與計畫的醫療機構所提供的慢性病照護管理（CCM）及遠端病患監測（RPM）服務。根據第三方產業報告，隨著醫療服務提供者持續轉向價值導向及居家照護模式，美國 RPM 市場目前規模為 140 億美元，預計到 2030 年將達到約 290 億美元，年複合成長率（CAGR）為 12.6%。¹該試點計畫目前涵蓋多家醫療機構，由 Kare Clinicals MSO 代表參與的醫療機構及提供服務的醫療人員擔任帳務處理機構。此計畫旨在透過可擴展的營運流程及科技驅動的工作流程，支援患者參與、照護協調及縱向監測計畫。所有慢性病管理（CCM）及遠距患者監測（RPM）服務，均預期將由持有適當執照的醫療人員及參與實體，依照適用的聯邦與州醫療保健法律、給付要求及支付方計畫規則提供並進行帳務處理。相關企業表示，試點基礎設施已產生超過 1,500 筆理賠申請，並將作為未來擴展計畫的基礎，目標是逐步涵蓋更多醫療服務提供者。作為合作計畫的一部分，Wellgistics Health 擬運用其超過 6,500 家獨立藥局的網絡，協助識別並支援可能從 CCM 和 RPM 服務中受益的合資格患者。隸屬於 Wellgistics 藥局網絡的參與藥局，亦可能有機會參與與該計畫相關的臨床互動計畫。Wellgistics Health, Inc. 總裁兼執行長 Prashant Patel 表示：「我們相信，藥局互動、醫療提供者連結以及科技驅動的照護協調三者的融合，不僅能顯著改善患者治療成效，同時也能為獨立藥局創造新的經濟機會。透過此次與 Kare PharmTech 的試點合作，我們正建立一套基礎架構，旨在支援慢性病管理及遠程患者監測計畫中可擴展的患者參與模式。」Kare PharmTech 創辦人兼執行長米塔爾·帕內拉（Mital Panera）補充道：「我們一直致力於打造一個營運高效的醫療服務組織（MSO）平台，能夠協助醫療提供者進行照護協調與給付流程管理。透過與 Wellgistics Health 及其藥局網絡合作，我們相信能進一步擴大患者參與度、提升照護連續性，並為未來醫療服務提供者的成長建立可擴展的框架。」雙方指出，隨著擴展計畫持續推進，此試點計畫仍須視營運發展、醫療服務提供者參與度及法規遵循等因素而定。關於 Wellgistics Health, Inc.Wellgistics Health（納斯達克代碼：WGRX）是健康資訊科技領域的領導者，將其專有的藥房調劑優化人工智慧平台 EinsteinRx™ 整合至其獲得專利的區塊鏈智慧合約平台 PharmacyChain™ 中，以優化處方藥調劑流程。其整合平台串聯了 6,500 多家藥局（「Wellgistics 藥局網絡」）及 200 多家製造商，提供批發分銷、數位處方箋傳輸、直接送達患者，以及由人工智慧驅動的樞紐服務，例如資格審核、用藥遵從性管理、新用戶註冊、事前授權，以及依需求提供的自費處方箋履約服務，以優化患者的用藥可及性。Wellgistics 提供端到端的解決方案，旨在為美國獨立藥房恢復處方藥市場的獲取管道、透明度及信任。關於 Kare PharmTech, LLC關於 Kare PharmTech, LLCKare Clinicals 隸屬於 Kare PharmTech, LLC 旗下更廣泛的企業生態系統，該公司由 Kiran Patel 博士掌控。Patel 博士於 1992 年創立了 Medicaid 服務供應商 WellCare，並於 2002 年以 2 億美元的價格將其出售。2007年，帕特爾博士創立了 America's 1st Choice Holdings，並收購了 Freedom Health 和 Optimum Holdings。2017年，他將 America's 1st Choice Holdings 出售給 Anthem, Inc.。帕特爾博士是一位知名慈善家，曾獲《佛羅里達趨勢》雜誌評選為「年度佛羅里達人」。前瞻性陳述本新聞稿包含《1995年私人證券訴訟改革法案》所定義的前瞻性陳述。前瞻性陳述包括有關本公司預期、信念、計劃、目標、意圖、策略、未來事件或表現的陳述，包括關於與 Kare PharmTech 及 Kare Clinicals 進行的試點合作所帶來的潛在效益、可擴展性、擴展、商業化、供應商參與、報銷機會、患者參與計劃、營運能力及未來發展，以及 Wellgistics 藥房網絡在支援 CCM 和 RPM 計劃方面預期所扮演的角色。諸如「預期」、「相信」、「可能」、「期望」、「意圖」、「或許」、「計劃」、「潛在」、「預測」、「尋求」、「應」、「將」等詞彙及類似表述，旨在識別前瞻性陳述。這些前瞻性陳述基於當前的預期與假設，並涉及可能導致實際結果與該等陳述所表達或暗示者存在重大差異的風險與不確定性。此類風險與不確定性包括但不限於：與醫療服務提供者採用與參與相關的風險、報銷結果、患者參與程度、營運執行、試點計畫的可擴展性、監管與醫療保健合規考量、適用法律或報銷政策變更、市場對本公司服務的接受度、競爭因素，以及本公司建立並維持戰略關係及成功實施其商業策略的能力。本新聞稿所述之試點合作屬探索性質，無法保證該計畫將帶來擴大的商業關係、重大營收機會或長期營運成功。有關上述及其他風險的更多資訊，可參閱本公司向美國證券交易委員會提交的文件，包括其中所載的風險因素。除法律規定外，本公司無義務因新資訊、未來事件或其他原因而更新或修訂任何前瞻性陳述。Wellgistics 媒體與投資者聯絡資訊媒體：media@wellgisticshealth.com投資者關係：IR@wellgisticshealth.com[1] MarketsandMarkets - 美國遠程患者監測市場報告來源：Wellgistics Health, Inc. Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Highlights:According to third-party industry reports, the U.S. RPM market is currently $14 Billion alone and expected to reach approximately $29 Billion by 2030, representing a 12.6% CAGR, as healthcare providers continue shifting toward value-based and home-based care models¹Pilot initiative launched across multiple provider offices focused on chronic care management (CCM) and remote patient monitoring (RPM) through it's MSO infrastructureApproximately 1,500+ claims generated to date through the pilot infrastructure with expansion roadmap targeting additional providersWellgistics Pharmacy Network of 6,500+ independent pharmacies positioned to support patient engagement and care coordination initiativesParticipating pharmacists expected to gain access to new clinical service revenue opportunitiesTAMPA, FLA., May 13, 2026 - (ACN Newswire via SeaPRwire.com) - Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics" or the "Company"), a leading healthcare technology and pharmaceutical distribution company, today announced a pilot collaboration with Kare PharmTech and Kare Clinicals integrating its MSO infrastructure to support chronic care management ("CCM") and remote patient monitoring ("RPM") services across participating provider offices. According to third-party industry reports, the U.S. RPM market is currently $14 Billion and expected to reach approximately $29 Billion by 2030, representing a 12.6% CAGR, as healthcare providers continue shifting toward value-based and home-based care models.¹The pilot program currently includes multiple provider offices, with Kare Clinicals MSO serving as the billing provider on behalf of participating offices and rendering providers. The initiative is designed to support patient engagement, care coordination, and longitudinal monitoring programs through scalable operational and technology-enabled workflows. All CCM and RPM services are expected to be furnished and billed by appropriately licensed providers and participating entities in accordance with applicable federal and state healthcare laws, reimbursement requirements, and payor program rules.The companies stated that the pilot infrastructure has already generated 1,500+ claims and is intended to serve as the foundation for broader expansion efforts targeting approximately additional providers over time. As part of the collaboration, Wellgistics Health intends to leverage its network of more than 6,500 independent pharmacies to help identify and support eligible patients who may benefit from CCM and RPM services. Participating pharmacies within the Wellgistics Pharmacy Network may also have opportunities to participate in clinical engagement initiatives associated with the program.Prashant Patel, President and CEO of Wellgistics Health, Inc., stated, "We believe the convergence of pharmacy engagement, provider connectivity, and technology-enabled care coordination represents a significant opportunity to improve patient outcomes while creating new economic opportunities for independent pharmacies. Through this pilot collaboration with Kare PharmTech, we are establishing infrastructure designed to support scalable patient engagement models across chronic care management and remote patient monitoring programs."Mital Panera, Founder and Chief Executive Officer of Kare PharmTech, added, "Our focus has been on building an operationally efficient MSO platform capable of supporting providers with care coordination and reimbursement workflows. By collaborating with Wellgistics Health and its pharmacy network, we believe we can further expand patient participation, improve continuity of care, and create a scalable framework for future provider growth."The companies noted that the pilot program remains subject to ongoing operational development, provider participation, and regulatory compliance considerations as expansion efforts continue.About Wellgistics Health, Inc.Wellgistics Health (NASDAQ:WGRX) is a health information technology leader, integrating proprietary pharmacy dispensing optimization artificial intelligence platform EinsteinRx™ into its patented blockchain-enabled smart contracts platform PharmacyChain™ to optimize the prescription drug dispensing journey. Its integrated platform connects 6,500+ pharmacies (the "Wellgistics Pharmacy Network") and 200+ manufacturers, offering wholesale distribution, digital prescription routing, direct-to-patient delivery, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment as needed to optimize patient access. Wellgistics provides end-to-end solutions designed to restore access, transparency, and trust in the U.S. prescription drug market for independent pharmacies.About Kare PharmTech, LLCKare Clinicals is part of the larger ecosystem of companies owned by Kare PharmTech, LLC, a company controlled by Dr. Kiran Patel. Dr. Patel founded Medicaid provider WellCare in 1992 and sold it in 2002 for $200 million. In 2007, Dr. Patel founded America's 1st Choice Holdings and acquired Freedom Health and Optimum Holdings. In 2017, he sold America's 1st Choice Holdings to Anthem, Inc. Dr. Patel is a noted philanthropist and was named Floridian of the Year by Florida Trend Magazine.Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the Company's expectations, beliefs, plans, objectives, intentions, strategies, future events, or performance, including statements regarding the potential benefits, scalability, expansion, commercialization, provider participation, reimbursement opportunities, patient engagement initiatives, operational capabilities, and future development of the pilot collaboration with Kare PharmTech and Kare Clinicals, as well as the anticipated role of the Wellgistics Pharmacy Network in supporting CCM and RPM initiatives. Words such as "anticipate," "believe," "could," "expect," "intend," "may," "plan," "potential," "project," "seek," "should," "will," and similar expressions are intended to identify forward-looking statements.These forward-looking statements are based on current expectations and assumptions and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Such risks and uncertainties include, without limitation, risks relating to provider adoption and participation, reimbursement outcomes, patient engagement levels, operational execution, scalability of the pilot program, regulatory and healthcare compliance considerations, changes in applicable laws or reimbursement policies, market acceptance of the Company's services, competitive factors, and the Company's ability to develop and maintain strategic relationships and successfully implement its business strategy.The pilot collaboration described in this press release is exploratory in nature, and there can be no assurance that the initiative will result in expanded commercial relationships, material revenue opportunities, or long-term operational success.Additional information regarding these and other risks can be found in the Company's filings with the U.S. Securities and Exchange Commission, including the risk factors contained therein. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.Wellgistics Media & Investor ContactMedia: media@wellgisticshealth.comInvestor Relations: IR@wellgisticshealth.com[1] MarketsandMarkets - U.S. Remote Patient Monitoring Market ReportSOURCE: Wellgistics Health, Inc. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年5月13日 - (亞太商訊 via SeaPRwire.com) - 近日，標普全球（S&P Global）在其發佈的最新簡報中明確表示，預計國泰海通集團下屬公司國泰君安國際控股有限公司（「國泰君安國際」、「公司」，股份代號：1788.HK）及其直接控股公司國泰海通金融控股有限公司（「國泰海通金控」）作為母公司國泰海通證券股份有限公司（「國泰海通」）核心子公司，將繼續在集團國際化戰略中發揮關鍵作用。標普全球在簡報中指出，國泰君安國際與母公司在投資銀行及財富管理領域的業務協同效應顯著，進一步強化了其在集團內部的重要性。國際化發展為國泰海通的核心戰略重點之一，國泰君安國際將繼續在集團加強全球佈局的過程中扮演關鍵角色。2025年，國泰君安國際及國泰海通金控分別實現利潤增長284%及85%，分別占國泰海通證券當年淨利潤約3%及8%。這一強勁的財務表現，有力印證了公司對集團整體業務發展的貢獻。標普全球預期，國泰君安國際未來兩年仍將作為集團核心子公司之一，持續獲得母公司支持，其發行人信用評級及「穩定」展望將與母公司保持同步。標普全球認為，公司可獲得母公司穩定、及時的支持，包括在必要時通過國泰海通間接受益於上海政府的資源。這份簡報充分反應了公司的現況及對未來發展的預期。國泰君安國際將堅定不移地配合集團國際化戰略，持續提升自身的專業能力及與集團的業務協同效率，為國泰海通集團成為具備國際競爭力與市場引領力的一流投資銀行作出貢獻。注：本文內容基於標普全球評級於2026年5月5日發佈的獨立觀點檔（Tear Sheet：Guotai Junan International Holdings Ltd. And Guotai Haitong Financial Holdings Ltd.），該文件不構成評級行動。關於國泰君安國際國泰海通集團下屬公司國泰君安國際（股票代號：1788.HK），是中國證券公司國際化的先行者和引領者，公司是首家通過IPO於香港聯合交易所主機板上市的中資證券公司。國泰君安國際以香港爲業務基地，幷在新加坡、越南和澳門設立子公司，業務覆蓋全球主要市場，爲客戶境外資産配置提供高質量、多元化的綜合性金融服務，核心業務包括財富管理、機構投資者服務、企業融資服務、投資管理等。目前，國泰君安國際已分別獲得穆迪和標準普爾授予「Baa2」及「BBB+」長期發行人評級，MSCI ESG「AAA」評級, Wind ESG「A」評級及商道融綠ESG「A」評級，同時其標普全球ESG評分領先全球81%同業。公司控股股東國泰海通證券（股票代號：601211.SH/2611.HK）爲中國資本市場長期、持續、全面領先的綜合金融服務商。更多關于國泰君安國際的資訊請見:https://www.gtjai.com   Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, May 13, 2026 - (ACN Newswire via SeaPRwire.com) - Recently, in its latest Tear Sheet, S&P Global stated that it expects Guotai Junan International Holdings Limited (“Guotai Junan International” or “GTJAI”, Stock Code: 1788.HK), a subsidiary of Guotai Haitong Group, and its intermediate holding company Guotai Haitong Financial Holdings Ltd.  (“GTHTFH”), to continue to play a key role in the international strategy of their ultimate parent Guotai Haitong Securities Co. Ltd. (“GTHT”).In its Tear Sheet, S&P Global pointed out that the business synergies between GTJAI and its parent company, particularly in investment banking and wealth management, reinforce its importance within the group. International development is one of GTHT’s core strategic priorities, and GTJAI will continue to play a key role in the Group’s efforts to strengthen its global presence. In 2025, GTJAI and GTHTFH recorded 284% and 85% profits growth, respectively, and accounted for about 3% and 8% of GTHT’s net profit during the year. This strong financial performance robustly demonstrates the Company’s contribution to the overall business of the Group.S&P Global expects that GTJAI will remain one of the Group’s core subsidiaries over the next two years and will continue to receive support from GTHT, with its issuer credit rating and “stable” outlook moving in tandem with those of the parent. S&P Global believes that GTJAI has access to timely parental support, including indirect benefits from the Shanghai government through GTHT if needed.This Tear Sheet fully reflects the Company’s current situation and expectations for future development. GTJAI will resolutely align with the Group’s international strategy, continuously enhance its own professional capabilities and the efficiency of business synergies with the Group, and contribute to Guotai Haitong Group’s goal of becoming a first-class investment bank with international competitiveness and market leadership.Note: This article is based on an independent opinion document (Tear Sheet: Guotai Junan International Holdings Ltd. And Guotai Haitong Financial Holdings Ltd.) published by S&P Global Ratings on May 5, 2026. This document does not constitute a rating action.About GTJAIGuotai Junan International (Stock Code: 1788.HK), a subsidiary of Guotai Haitong Group, is the market leader and first mover for internationalization of Chinese Securities Company as well as the first Chinese securities broker listed on the Main Board of The Hong Kong Stock Exchange through initial public offering. Based in Hong Kong with subsidiaries in Singapore, Vietnam and Macau, GTJAI’s business covers major markets around the world, offering high-quality and diversified comprehensive financial services for clients' overseas asset allocation. Core business includes wealth management, institutional investor services, corporate finance services, investment management and other business. GTJAI has been assigned “Baa2” and “BBB+” long term issuer rating from Moody and Standard & Poor respectively, as well as an MSCI ESG “AAA” rating, Wind ESG “A” rating and SynTao Green Finance “A” rating in ESG. Additionally, its S&P Global ESG score leads 81% of its global peers. The controlling shareholder, Guotai Haitong Securities (Stock Code: 601211.SH/ 2611.HK), is the comprehensive financial provider with a long-term, sustainable and overall leading position in the China’s capital markets. For more information about GTJAI, please visit https://www.gtjai.com.     Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, May 13, 2026 - (ACN Newswire via SeaPRwire.com) - The sixth Asia Summit on Global Health (ASGH), jointly organised by the Government of the Hong Kong Special Administrative Region and the Hong Kong Trade Development Council (HKTDC), and the 17th Hong Kong International Medical and Healthcare Fair (Medical Fair), organised by the HKTDC and co-organised by the Hong Kong MedTech Association, have concluded successfully. As one of the two flagship events of International Healthcare Week, the ASGH gathered some 3,000 participants from 43 countries and regions and arranged over 400 one‑on‑one deal-making meetings, while also facilitating the signing of multiple cooperation agreements, with a strong focus on the application of artificial intelligence. Meanwhile, the Medical Fair welcomed some 13,000 buyers from 61 countries and regions for sourcing and networking. More than 670 business matching meetings were arranged during the fair, supporting buyers and exhibitors in identifying potential partners and advancing concrete business discussions. Together, the two flagship events facilitated over 1,000 high-quality collaborations and connections, fully demonstrating the synergy between medical technology, investment and industry applications.Over 90 global leaders share insight into healthcare innovation development and AI applicationsThe sixth ASGH, a two-day event jointly organised by the Government of the Hong Kong Special Administrative Region and the HKTDC, has concluded under the theme Fuelling Healthcare Breakthroughs, focusing on public health, frontier healthcare technologies, AI breakthroughs, healthcare investment and the silver health. The ASGH brought together over 90 international healthcare officials, scientific pioneers, Nobel laureate, investors and corporate leaders to share insight and explore pathways to accelerate innovation across the global healthcare ecosystem.At Plenary Session I – Strengthening Pandemic Preparedness through Global Collaboration. Prof Ibrahim Abubakar, Vice‑Provost (Health) and Professor of Infectious Disease Epidemiology, University College London, said: “Research platforms need to be developed long in advance of pandemics, and we must invest in infectious disease infrastructure, and beyond, whether it’s in AI technology or in  disease management.”Plenary Session II – Fuelling Healthcare Breakthroughs centred on the commercialisation of medical research, biomedical innovation and healthcare investment opportunities. Jonathan Symonds, Chair of GSK, said: “All developed countries are now facing ageing, low birth rates and an increasing impact of chronic disease. So, it's no longer just a health system problem, but it's now an economic problem.”During the Dialogue with Global Pioneer in Health session, Prof Michael Levitt, 2013 Nobel Laureate in Chemistry and Robert W and Vivian K Cahill Professor of Cancer Research at the Stanford University School of Medicine, said that Hong Kong’s healthcare system possesses unique advantages and high-quality statistical data, making it potentially more valuable for research than the US and other countries or regions, in  areas such as longevity.The ASGH featured multiple thematic sessions spotlighting the application of AI in healthcare. Sustaining the momentum of the “Intelligence at Scale: How AI is Powering Real-World Healthcare Revolution” session on the first day, another thematic session on the second day, “Transforming Healthcare through Digital Health & AI Innovations”, explored how digital technologies and artificial intelligence are reshaping healthcare systems. Natasha Chhatrapati, Senior Director, Business Transformation Lead for International, Pfizer Inc., said: “AI is compressing timelines across the entire healthcare journey, from drug development and clinical research to how we engage with physicians and how patients consume care.”The session “The Next Frontier in China’s Healthcare Industry” examined strategies to advance the Chinese Mainland healthcare sector. Dr James Xue, Founder, Chairman and CEO of CANbridge Pharmaceuticals Inc, said: “China has an edge because of the population. A bigger population base will allow companies to build better drug candidates.”With silver health emerging as a major global focus, the Silver Health Chapter included the session “Unlocking Growth in Silver Health: From Precision Medicine to Smart Ageing Innovations”, which brought together leading experts to discuss challenges and opportunities arising from population ageing. Dr Alex Mihailidis, Associate Vice‑President, International Partnerships and Professor at the University of Toronto and Scientific Director at AGE‑WELL, provided in‑depth insight into breakthroughs in prevention and treatment of age‑related diseases, offering guidance for the development of the silver health economy and smart ageing solutions. He said: “For a technology to be successful with older people, it’s not just the technology, but also the service delivery model, as well as the practice and policy.”The newly introduced session “CSO Insights: Catalysing Scientific Breakthroughs and Investments for Future Health” featured discussions on research strategy and the acceleration of scientific discoveries into practical applications. Dr Li Xiang, Senior Vice President, Co-President and Chief Scientific Officer, Innovative Medicines Division, Fosun Pharma, said: “In our business, it is very important to begin with the end in mind. When you set out to do your discovery program, you must already know what the unmet needs are and how difficult the clinical trials will be.”Over 400 deal‑making sessions drive investment and business matchingBeyond thought leadership, the ASGH continued to serve as an effective platform for deal‑making and investment matching. Dedicated deal-making at the ASGH facilitated one‑to‑one meetings to promote tangible collaboration.During the ASGH, over 400 business and investment matching meetings were arranged, attracting investment institutions and healthcare enterprises from Europe, the US, Asia and the Guangdong‑Hong Kong‑Macao Greater Bay Area to explore opportunities in investment, technology deployment and market expansion.Colin Tan, Director of Operations at TusPark Holdings, an investor from the UK, said: “This year, I brought around 15 UK healthcare and life sciences companies to exhibit at the UK Pavilion. The ASGH has been an excellent platform to forge such connections. We are now facilitating a significant partnership in cancer research between a leading UK organisation and a Hong Kong counterpart.”ASGH also featured the ASGH Business Hub and the InnoHealth Showcase, bringing together some 180 healthcare innovation companies from 12 countries and regions to present cutting‑edge solutions across biotechnology, digital health and medical technologies.Strategic Partner of this year’s Summit, Shanghai Industrial Investment (Holdings) led multiple subsidiaries in exhibiting at the ASGH. Gu Feng, Chief Finance and Investment Officer, said that the ASGH fully showcased Hong Kong’s international competitiveness: “Chinese companies expanding overseas will come to Hong Kong, and foreign companies seeking to procure will do the same. Here we can not only acquire resources, but also connect and match resources, talent, capital, and other key elements.”AQ Biotech from Finland, exhibiting at ASGH for the first time, said that their objective was to explore the Asian market. They view Hong Kong as a vital hub that adds internationally recognised credibility, connectivity and commercial acumen, helping them take their work global.Dr Iman Manavitehrani, Founder and Director of SDIP Innovations, the Australian exhibitor returning for the second year, said: “Last year’s visit led directly to an IGNITE grant from HSITP, and we are now part of the first Australian cohort based here. With Hong Kong as our gateway to the GBA and Chinese Mainland, I am confident the connections made at the ASGH will lead to further collaboration and partnership.”Third-time exhibitor, Prof Leung Kam-tong, Founder and CEO of local healthcare startup Homing Pharmaceuticals, said: “We’ve already reconnected with three investors here for in-depth discussions on our fundraising strategy, taking our navigated CAR-T therapy to first-in-human clinical trials. Sessions outside my field sparked new ideas around refining the therapy and exploring new directions. I also met professors from Australia and Singapore, and look forward to exploring international R&D collaborations as we bring this therapy worldwide.”Building bridges for “go global” and other cross‑border healthcare collaborationsBuilding on its track record of facilitating collaboration, the ASGH enabled the signing of 10 Memoranda of Understanding (MoUs), such as those between the HKSH Medical Group and Siemens Healthineers, as well as Australian AI-powered clinical documentation platform startup Heidi Health, which signed separate agreements with local medical group EC Healthcare and Hong Kong Metropolitan University. These collaborations will drive deeper cooperation, including AI‑enabled healthcare applications and clinical research, further reinforced the ASGH’s role as a bridge connecting the Chinese Mainland and international healthcare ecosystems. Notably, HKSH Medical Group and Siemens Healthineers signed an agreement, formally establishing HKSH as Siemens Healthineers’ first Photon Counting Computed Tomography Simulation (PCCT-Sim) Reference Site in Asia.On the second day, the GoGlobal CONNECT series: Hong Kong as a Superconnector to Empower Global Expansion of Pharmaceutical Enterprises workshop brought together experts in regulation, clinical trials, IP protection and distribution to share practical insight on international expansion. Prof Bernard Cheung, Chief Executive Officer, Greater Bay Area International Clinical Trial Institute, said: “Public hospitals in Hong Kong have very good electronic medical records that go back 30 years. It’s a unique asset that benefits not just people in Hong Kong but the world, as it allows us to study the long-term progression of diseases.”The ASGH also featured the “GoGlobal Connect” and the Business of Healthcare Advisory Zone, enabling healthcare enterprises to connect with service providers and receive practical support for developing “go global” strategies. Xiang Jun, Chairman of 365 Intelligence (Beijing) Medical Technology Co., Ltd, said that the ASGH helped them gain a deeper understanding of Hong Kong’s professional services and of HKTDC’s “GoGlobal Connect” initiative. The company is particularly interested in Hong Kong’s research data and service resources, and plans to establish research operations in Hong Kong in the long term. Mark Xu, Regional Director of Sales and Marketing, Guangzhou Wondfo Biotech Co, Ltd, also successfully connected with service providers, including DKSH and the Greater Bay Area International Clinical Trial Institute, through this workshop. They engaged in in-depth discussions on potential collaboration opportunities for “going global”.During the summit, the HKTDC signed a Memorandum of Understanding with the Hong Kong Singapore Business Association (HSBA), supporting Mainland enterprises’ “going global” via Hong Kong to target the Singapore and ASEAN markets. Prime Minister and Minister for Finance of Singapore Lawrence Wong visited Hong Kong in March this year, during which both governments agreed to deepen cooperation. The HSBA and the HKTDC, together with professional service providers, plan to strengthen trade and economic ties between the two cities. By leveraging their respective strengths and promoting complementary cooperation, they aim to drive business development, assist Chinese Mainland enterprises in expanding regionally and internationally, and enhance tripartite collaboration among Singapore, Hong Kong, and the Chinese Mainland.The Medical Fair brings together global industry players to foster diverse collaborations, strengthening Hong Kong’s status as a global healthcare hubThe Medical Fair was being held concurrently. Organised by the HKTDC and co-organised by the Hong Kong MedTech Association, the Medical Fair adopted the theme Innovations Boosting Smart Health Experience. Focusing on three key areas: MedTech, GeronTech, and Preventive Healthcare, the event provided a high-efficiency trade and matchmaking platform for global R&D institutions, manufacturers, and medical professionals to showcase the latest industry trends. The number of exhibitors featuring smart ageing products and green solutions doubled this year, with many showcasing innovative solutions integrating AI and robotics to meet evolving market demands.The Medical Fair featured some 300 exhibitors from 10 countries and regions, including Hong Kong, Chinese Mainland, Macao, Taiwan, Australia, Canada, Korea, New Zealand, United States and Vietnam. The Fair featured seven major zones, including Startup Zone, Hospital Equipment and Digital Health, Biotech and Lab Diagnostics, Laboratory Technologies and Healthcare Services, Medical Supplies, and the World of Health and Wellness, showcasing the latest medical technologies and innovative solutions. Pavilions from leading local universities, the Hong Kong Science and Technology Parks, and the Hong Kong MedTech Association underscored a multi-sector commitment to fostering collaborative innovation across government, industry, academia, research, and investment sectors.Exhibitors acknowledged that AI has become a core driver of healthcare services, while the Medical Fair serves as a one-stop platform that brings together a complete healthcare ecosystem, successfully integrating AI, robotics technology and a wide range of smart medical devices. Wong Cheung Hang, Sales and Marketing Manager of Health Care & Co, a medical and rehabilitation equipment company in Hong Kong, said, “Buyers showed particular interest in our AI management systems, AI-assisted robots and various smart healthcare applications. With healthcare providers increasingly adopting smart health solutions, the market outlook is promising. We expect this fair to drive at least 20% business growth compared with last edition and enable us to promote smart rehabilitation technologies.”  Many overseas exhibitors succeeded in securing business matching opportunities at the fair. Peter Li, Chief Executive Officer of first-time exhibitor GenomeMe Lab Inc from Canada, said, “We connected with buyers from Hong Kong, Thailand and India, and identified potential local partners in the healthcare and hospital sectors. This will help us explore entry into hospital channels, establish distribution networks, and lay the groundwork for future expansion into Southeast Asia, Australia and Korea.”The Medical Fair has facilitated numerous cross-regional collaborations, serving as a key platform for industry exchange and business matching. Dresio Limited, participating in the Fair for the third time under the banner of Hong Kong Science and Technology Parks, showcased its contactless physiotherapy assessment system Accudex, drawing strong interest from buyers across Hong Kong, Chinese Mainland, Singapore and the Philippines. Curtis Wong, Chief Operating Officer and Head of Research and Development of the company, said, “This year’s fair outperformed previous editions in footfall, business exchanges and partnership discussions. We have engaged with a large number of high-quality buyers from hospitals, rehabilitation centres and the insurance sector.” The company met with a Filipino buyer on the first day of the exhibition and subsequently signed a Memorandum of Understanding (MOU) on the third day, expanding its software into Southeast Asia, with the contract value expected to exceed HK$1 million.The Medical Fair was held concurrently with the ASGH and the Hospital Authority (HA) Convention, bringing together key industry stakeholders and generating strong synergy. Exhibitors were able to seize the opportunity to meet with numerous representatives from the Hospital Authority and major healthcare institutions, fostering meaningful exchanges and collaboration. Among them, first-time exhibitor PalmX Technology Limited showcased its palm vein biometric technology at the Startup Zone. Jeffrey Lo, Vice President of the company, was impressed by the Fair’s response, which exceeded his expectations. He added that within the first two days, they received over 20 enquiries from hospitals and healthcare institutions, including representatives from the Hospital Authority, and attracted interest from overseas buyers in Thailand, Indonesia, the Philippines and India, with potential orders ranging from US$10,000 to several hundred thousand dollars.This year’s Medical Fair attracted a significant number of buyers from emerging markets seeking sourcing opportunities. Dr Keo Sovann, an otorhinolaryngologist from Orchid Hospital in Cambodia who visited the fair specifically for new medical equipment, said, “I met more than 10 exhibitors from Chinese Mainland, Australia and Malaysia, which has helped expanding our hospital’s procurement network and advanced our internationalization efforts. I am particularly interested in a Hong Kong company’s AI-powered medical imaging solutions and X-ray equipment; we are considering an order of 20 units.” A buyer from Morocco also attended the fair for the first time to source laboratory equipment. Rachid Zemmouri, Business Development Manager of Promamec, said he met with at least 15 exhibitors from Hong Kong, Chinese Mainland, Taiwan and Indonesia. Discussions are underway on thermodynamics-related solutions with the aim of application to eye-disease treatment. Subject to satisfactory progress, he plans to invite partners to Morocco for site visits. He added that the company has an annual procurement budget of approximately US$70 million and intends to return for future sourcing.The Fair hosted over 50 themed forums and seminars, with leading technology companies, industry experts and academics sharing the latest industry trends, technological innovations and practical insights to foster in-depth exchange, collaboration and inspire trade buyers. Highlight sessions included “Accelerating Mental Health Innovation through AI Research and Adoption”, “HKMTA Medical Fair Forum 2026: The Medtech Solutions - Greater Bay Area & Overseas”, “The ASEAN Gateway: Navigating Regulations, Capital and Distributions from Hong Kong”, and “Decoding the Demand for Gerontechnology” among others, all of which attracted strong audience engagement. Selected sessions are available for replay on the Fair’s website for extended engagement.The exhibition continued to adopt the EXHIBITION+ hybrid model. Global exhibitors, industry professionals, and buyers could make use of the Click2Match and explore sourcing opportunities via HKTDC Sourcing. Click2Match will remain available until 20 May.Photo download: https://bit.ly/4nokRfTThe sixth Asia Summit on Global Health was attended by some 3,000 participants from 43 countries and regions.Dr Alex Mihailidis, Associate Vice President, International Partnerships and Professor at the University of Toronto and Scientific Director at AGE WELL, attended and shared his insight.In the session Transforming Healthcare through Digital Health & AI Innovations, Natasha Chhatrapati, Senior Director, Business Transformation Lead for International at Pfizer Inc, engaged with fellow panellists to examine the practical implementation and the latest breakthroughs in AI within the healthcare sector.On the second day, the GoGlobal CONNECT series: Hong Kong as a Superconnector to Empower Global Expansion of Pharmaceutical Enterprises brought together experts in regulation, clinical trials, IP protection and distribution to share practical insights on international expansion.During the ASGH, over 400 business and investment matching meetings were arranged, attracting investment institutions and healthcare enterprises from Europe, Asia and the Guangdong‑Hong Kong‑Macao Greater Bay Area to explore opportunities in investment, technology deployment and market expansion.The ASGH also featured the ASGH Business Hub and the InnoHealth Showcase, bringing together around 180 healthcare innovation companies from 12 countries and regions to present cutting‑edge solutions across biotechnology, digital health and medical technologies.The ASGH also featured the “GoGlobal Connect” and the Business of Healthcare Advisory Zone, enabling healthcare enterprises to connect with service providers and receive practical support for developing “go global” strategies.HKTDC signed a Memorandum of Understanding with the Hong Kong Singapore Business Association (HSBA), supporting Mainland enterprises to “go global” via Hong Kong and target the Singapore and ASEAN markets.The 17th Hong Kong International Medical and Healthcare Fair attracted buyers from 61 countries and regions, with some 13,000 buyers visiting the fair for sourcing and procurement.The Hong Kong MedTech Association led some 20 companies to exhibit at the fair, drawing strong buyer interest and encouraging in‑depth business discussions.The Canada Pavilion brought together a number of companies to promote their medical equipment, technology application solutions and related services, attracting buyers to explore opportunities and engage in business discussions.Hong Kong Science and Technology Parks Corporation led over 30 innovation and technology companies to exhibit at the Fair, showcasing the strength of Hong Kong’s local medical innovation and R&D capabilities.Industry experts at the themed session “ASEAN Gateway: Navigating Regulations, Capital and Distributions from Hong Kong” shared the latest market trends, fostering active exchanges among industry stakeholders.WebsitesInternational Healthcare Week: https://internationalhealthcareweek.hktdc.com/enAsia Summit On Global Health: https://www.asiasummitglobalhealth.com/conference/asgh/enHong Kong International Medical and Healthcare Fair: https://www.hktdc.com/event/hkmedicalfair/enList of Product: https://www.hktdc.com/event/hkmedicalfair/en/product  Media enquiriesYuan Tung Financial Relations:Jasmine ZhangTel: (852) 3428 3278Email: jzhang@yuantung.com.hkLouise SongTel: (852) 3428 5691Email: lsong@yuantung.com.hkTiffany LeungTel: (852) 3428 2361Email: tleung@yuantung.com.hkHKTDC’s Communications & Public Affairs Department:Noah QiuTel: (852) 2584 4575Email: noah.yl.qiu@hktdc.orgNavin LawTel: (852) 2584 4525Email: navin.cm.law@hktdc.orgSerena CheungTel: (852) 2584 4137Email: jane.mh.cheung@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) celebrates its 60th anniversary this year. The HKTDC is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in the Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus.  Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

美國佛羅里達州奧蘭多，2026年5月13日 - (亞太商訊 via SeaPRwire.com) - 在 2026 SAP Sapphire 大會上，SAP SE（紐交所代號：SAP）正式發布「自主營運企業（Autonomous Enterprise）」願景，旨在優化全球最核心的業務流程，讓人與 AI 無縫協作，在安全可控的前提下，以更高效率、更具策略性的方式，應對日益增長的全球商業需求。SAP 全球CEO柯睿安（Christian Klein）表示：「對於客戶的關鍵任務流程而言，『差不多對』是遠遠不夠的。透過將 SAP Business AI 平台與 SAP自主型管理套件(Autonomous Suite) 結合，我們把 AI agents 深度嵌入業務流程、數據及治理框架之中，確保其能夠提供準確、合乎規格且安全的結果，從而開拓全新增長機遇，並帶來實質的成本節省與效率提升。」Autonomous Enterprise包含一個統一的 AI 平台，用於構建及治理 AI agents，並為其提供業務脈絡；同時亦包括一個可執行核心業務流程的自主型管理套件，以及重新定義人與企業軟件互動方式的全新用戶體驗。推出 SAP Business AI平台SAP Business AI作為全新的基礎平台，專為構建及部署基於真實業務場景的企業級 AI 而設。SAP Business AI 平台將 SAP Business Technology Platform、SAP Business Data Cloud 及 SAP Business AI 整合於一個統一、受監管的環境中。SAP Business AI 平台的核心為 SAP Knowledge Graph，它就像為 AI agents 提供一張結構化的業務地圖，清晰呈現客戶 SAP 系統環境中的每個業務實體、流程及關聯。Joule Studio 是 SAP 面向企業 AI agents、應用程式及 AI agent 工作流構建的 AI 優先解決方案。開發人員可利用 SAP 提供的安全、可擴展，並專為企業級 AI 優化的託管基礎設施，使用自己偏好的無程式碼、專業程式碼及 AI 開發框架進行開發。跨業務職能及行業中部署SAP Autonomous Suite在此基礎上，SAP 亦進一步推出 SAP Autonomous Suite。讓現有業務應用具備 AI agents 能力，從而端到端自主執行業務流程。該套件於財務、供應鏈、採購、人力資本管理及客戶體驗等範疇，部署超過 50 個按業務領域專屬（Domain-specific）的 Joule Assistants。這些assistants透過協調逾 200 個專門 AI agents，實現端到端流程全自動化。例如，全新的Autonomous Close Assistant可透過自動處理日記賬、對賬及錯誤修正，將財務結賬流程由數星期縮短至數天。此外，SAP 發布了 Industry AI，透過七大行業自主型解決方案，進一步擴展其深厚的行業能力。這些方案不僅可端到端執行完整的行業流程，更內置特定行業專屬業務邏輯、數據模型及規格與監管要求。在本次大會上，SAP 展示了與歐洲能源巨頭RWE的合作成果，利用Industry AI幫助減少其海上風力渦輪機的意外停機時間。借助 SAP 的 Autonomous Asset Management 場景，AI agents 可分析數千宗歷史事故數據，識別最可能的根本原因，並自動生成已預填的工作單，附上合適工具建議及有效的修復方案。設計自主型用戶體驗Joule Work也是今次大會的重點發布之一，重新定義了用戶與 SAP 軟件的互動方式。用戶現在不再需要在各個應用之間切換，或於多個畫面手動輸入資料，而是可以直接與 Joule 互動。只要描述所需的業務成果，Joule 便會協調合適的工作流程、數據及 AI agents 完成任務。Joule Work 不單止是對話工具，更會主動呈現相關業務洞察，並在背景自動處理日常任務，令工作即使在人类未主動操控時亦能持續推進。該方案將支援桌面、流動裝置及語音操作，並可跨 SAP 及非 SAP 系統使用。投資1億歐元　加快客戶邁向自主營運SAP 全面升級了客戶及合作夥伴計劃，加快各類企業轉型邁向 Autonomous Enterprise。為促進落實及採用，SAP設立了一項1億歐元的專屬基金，用於支援合作夥伴協助客戶部署由 SAP 開發的 AI assistants 及 AI agents。該基金亦用於支持合作夥伴基於Joule Studio，在 SAP Business AI 平台上延伸或開發全新合作夥伴 AI agents。SAP 同時升級 RISE with SAP 與 SAP GROW 的方案權益，以促進客戶採用 AI。兩者均可使用 Joule Assistants產品組合；RISE with SAP客戶可於首年內啟用 3 個 Joule assistants，而 SAP GROW 客戶則可於上線後即獲得完整 Joule assistants方案的使用權。至於 SAP S/4HANA 本地部署客戶及 SAP ERP Central Component（SAP ECC）客戶，SAP 亦提供相應支援：客戶只要承諾將現有大部分系統遷移至 SAP Cloud ERP，即可獲得部分 AI 場景的使用權，從而在現有系統環境與雲端目標架構之間實現無縫過渡。此外，SAP 亦推出 agent-led transformation 的轉型工具，可將 ERP 系統遷移工作量減少 35%以上，透過大規模自動化系統分析、代碼修復、配置及測試，加快項目推進，並提升可預測性。此外，SAP 亦宣布全方位拓展策略合作夥伴關係︰- 在平台與套件層面：  - SAP將與Anthropic合作，將Claude基礎模型引入SAP的AI平台，用於支援涵蓋人力資源、採購及供應鏈等場景的 Joule Agentic AI；  - 與Amazon Web Services合作，實現SAP Business Data Cloud與Amazon Athena之間的零複製數據整合；  - 與Google Cloud及Microsoft合作，實現Joule 與外部Agentic AI框架之間的雙向agent-to-agent互操作；  - 與Mistral AI及Cohere合作，在SAP云基礎設施上提供主權模型選項；  - 與n8n合作，在Joule Studio內提供可視化AI工作流程編排能力；  - 與NVIDIA合作，借助其OpenShell為Joule Studio提供安全可靠的運行環境；  - 與Parloa合作，將AI agents引入SAP Service Cloud，使其可在全面存取業務數據與服務流程的基礎上，處理客戶互動。- 在實施層面︰  - SAP將與Palantir及Accenture圍繞複雜數據遷移場景展開合作，並與Conduct合作，推動AI驅動的SAP EPR Cloud遷移。更多內容請參閱《SAP Sappire 2026 創新新聞指南》圖片下載：https://bit.ly/42zNb5h關於SAP作為企業應用和商業AI的全球領導者，SAP位於商業和技術的交匯點。50多年來，企業一直信賴SAP通過整合財務、採購、人力資源、供應鏈和客戶體驗等核心業務營運，來發揮其最佳表現。如需瞭解更多SAP資訊，請瀏覽https://www.sap.com/hk 。如要查詢更多資訊，請聯絡（只限傳媒）：縱橫傳訊顧問有限公司（SCC）Andico Tsuiandico.tsui@sprg.com.hk+852 2114 4346 / 6902 3831 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ORLANDO, FL, May 13, 2026 - (ACN Newswire via SeaPRwire.com) - At SAP Sapphire in 2026, SAP SE (NYSE: SAP) introduced the Autonomous Enterprise to help enhance the world’s most critical business workflows, so that humans and AI work together to meet the accelerating demands of global business profitably, strategically and safely. “For the mission-critical processes of our customers, ‘almost right’ just isn’t good enough,” said Christian Klein, CEO of SAP SE. “By uniting SAP Business AI Platform with SAP Autonomous Suite, we anchor AI agents in the business processes, data and governance so they can deliver accurate, compliant and secure outcomes, unlocking new sources of revenue and meaningful cost savings.”The Autonomous Enterprise includes a unified AI platform for building, contextualizing and governing agents, an autonomous suite that executes core business operations and a new user experience that redefines how people work with enterprise software.Introducing SAP Business AI PlatformSAP Business AI Platform is a new foundation for building and deploying enterprise AI grounded in real business context. SAP Business AI Platform now unifies SAP Business Technology Platform, SAP Business Data Cloud and SAP Business AI into a single, governed environment.At its core is the SAP Knowledge Graph solution, which gives AI agents a structured map of business entities, processes and relationships across a customer’s SAP landscape. Joule Studio is SAP’s AI-first solution for building enterprise agents, applications and agentic workflows. Developers can build using the no-code, pro-code and AI frameworks of their choice on SAP-managed infrastructure that is secure, scalable and optimized for enterprise AI.Deploying SAP Autonomous Suite Across Every Business Function and IndustryBuilding on this foundation, SAP also introduced SAP Autonomous Suite, which enables SAP’s existing business applications with AI agents capable of running processes from start-to-finish.The suite will deploy more than 50 domain-specific Joule Assistants across finance, supply chain, procurement, human capital management and customer experience. These assistants will automate end-to-end processes by orchestrating a subset of over 200 specialized agents to execute precise tasks. For example, the new Autonomous Close Assistant can compress the financial close process from weeks to days by automating journal entries, reconciliation and error resolution across the entire process.SAP also launched Industry AI, expanding its deep industry portfolio through seven autonomous solutions that will enable start-to-finish industry processes and embed sector-specific process logic, data models and regulatory requirements. At SAP Sapphire, SAP showcased its work with European energy giant RWE to leverage Industry AI, helping reduce unplanned downtime across its offshore wind turbines. With SAP’s Autonomous Asset Management scenario, AI agents are designed to analyze data from thousands of past incidents, identify the likely root cause and generate pre-filled work orders with the right tools and proven fixes from other sites.Designing the Autonomous User ExperienceThe company also revealed Joule Work, redefining how users engage with SAP software. Instead of navigating individual applications and entering data across several screens, users will now interact primarily with Joule. By describing a desired business outcome, Joule will orchestrate the right combination of workflows, data and agents to get it done.Joule Work goes beyond conversation, proactively surfacing relevant insights and automating routine tasks behind the scenes so work moves forward even when humans aren’t actively steering it. It will be available on desktop, mobile and voice across SAP and non-SAP systems.Accelerating the Customer Journey Toward Autonomy with €100 Million InfusionSAP evolved its customer and partner programs to help accelerate the organization’s journey to the Autonomous Enterprise. To catalyze adoption, the company has launched a €100 million fund for SAP partners to help customers deploy SAP-built AI assistants and agents. The fund is also available to partners that extend or build new partner agents on the new SAP Business AI Platform using Joule Studio.SAP has enhanced its RISE with SAP and SAP GROW offerings to accelerate AI adoption. Both include access to the Joule Assistants portfolio; RISE with SAP customers will have three assistants activated within their first year, while SAP GROW customers receive full portfolio access at onboarding. SAP S/4HANA on-premises and SAP ERP Central Component (SAP ECC) customers are not excluded: those that commit to transitioning the majority of their current landscape to SAP Cloud ERP gain access to select AI scenarios, bridging the gap between their current landscape and their cloud destinationSAP also introduced new agent-led transformation tooling that can reduce ERP migration efforts by more than 35 percent, driving faster and more predictable projects by automating system analysis, code remediation, configuration and testing at scale.Lastly, SAP announced a full slate of strategic partnerships across each category:- Platform and suite partnerships include Anthropic, with Claude among the foundation models SAP’s AI platform will leverage to power Joule agents across HR, procurement and supply chain; Amazon Web Services, bringing zero-copy data integration between SAP Business Data Cloud and Amazon Athena; Google Cloud and Microsoft, enabling bidirectional agent-to-agent interoperability between Joule and external agent frameworks; Mistral AI and Cohere, delivering sovereign model options on SAP’s cloud infrastructure; n8n, providing visual AI workflow orchestration inside Joule Studio; NVIDIA, whose OpenShell provides the trusted secure runtime for Joule Studio; and Parloa, bringing AI agents into SAP Service Cloud to handle customer interactions with full access to business data and service processes.- Implementation partnerships include Palantir and Accenture, partnering on complex data migration scenarios, and Conduct for AI-powered cloud ERP migrations.Learn more in the SAP Sapphire 2026 Innovation News Guide.Visit the SAP News Center. Get SAP news via LinkedIn and Bluesky.Photo download: https://bit.ly/42zNb5hAbout SAPAs a global leader in enterprise applications and Business AI, SAP (NYSE: SAP) stands at the nexus of business and technology. For over 50 years, organizations have trusted SAP to bring out their best by uniting business-critical operations spanning finance, procurement, HR, supply chain, and customer experience. For more information, visit www.sap.com/hk.For more information, press only:Strategic Public Relations Group (SPRG)Andico TsuiEmail: andico.tsui@sprg.com.hkTel: 2114 4346 / 6902 3831 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

 Financial HighlightsFor the three months Ended 31 March 2026(HK$ million)20262025ChangeRevenue 1,115.61,071.9+ 4.1%Gross Profit402.1376.1+ 6.9%Gross Profit margin36.0%35.1%+ 0.9ppProfit attributable to owners of the Company122.4110.0+ 11.3%Net profit margin11.0%10.3%+ 0.7ppAdjusted EBITDA 209.0201.5+ 3.7%Earnings per share (HK cents)11.7310.54+ 11.3%HONG KONG, May 13, 2026 - (ACN Newswire via SeaPRwire.com) - Nissin Foods Company Limited (“Nissin Foods” or the “Company”, together with its subsidiaries, the “Group”; Stock code: 1475) today announced its unaudited first quarter financial results for the three months ended 31 March 2026 (the “Reporting Period”).The Group reported revenue of HK$1,115.6 million for the Reporting Period, representing an increase of 4.1% from HK$1,071.9 million of the corresponding period of 2025. Gross profit increased by 6.9% year-on-year to HK$402.1 million, due to the continued implementation of cost efficiency initiatives. Gross profit margin increased by 0.9 percentage points to 36.0% from 35.1% of the corresponding period of 2025 mainly attributable to the increased sales volume of the core brands to absorb cost pressure. Profit attributable to owners of the Company notably increased by 11.3% year-on-year to HK$122.4 million, while Adjusted EBITDA grew by 3.7% year-on-year to HK$209.0 million.Revenue from Hong Kong and other regions operations increased moderately by 3.1% due to the stable performance of the noodles business, particularly the Group’s core brands of Cup Noodles and Demae Iccho. As for the Chinese Mainland operations, revenue increased by 4.6% due to the sales expansion in the inland areas and the appreciation of Renminbi to Hong Kong Dollars.Mr Kiyotaka ANDO, Executive Director, Chairman and Chief Executive Officer of Nissin Foods, said, “Building on the solid momentum established in 2025, the Group delivered another quarter of resilient growth, with steady performance across our key markets. Revenue and profitability improved year-on-year, supported by stable sales volumes. Our core noodles business continued to perform well across regions, while our premiumisation and diversification strategies gained further traction in the Chinese Mainland. With a balanced regional footprint and enhanced operational execution, the Group remains well positioned to deliver sustainable growth and long-term value for shareholders.”About Nissin Foods Company LimitedNissin Foods Company Limited ("Nissin Foods”, together with its subsidiaries, the “Group”; Stock code: 1475) is a renowned food company in Hong Kong and the Chinese Mainland, with a diversified portfolio of well-known and highly popular brands, primarily focusing on the premium instant noodle segment. The Group officially established its presence in Hong Kong in 1984 and is the largest instant noodle company in Hong Kong. The Group primarily manufactures and sells instant noodles, high-quality frozen food products, including frozen dim sum and frozen noodles, and also sells and distributes other food and beverage products, including retort pouches, snacks, mineral water, sauce and vegetable products under its two core corporate brands, namely “NISSIN ” and “DOLL” together with a diversified portfolio of iconic household premium brands. The Group’s five flagship product brands, namely “Cup Noodles”, “Demae Iccho”, “Doll Instant Noodle”, “Doll Dim Sum” and “Fuku” are also among the most popular choices in their respective food product categories in Hong Kong. In the Chinese market, the Group has introduced technology innovation through the “ECO Cup” concept and primarily focuses its sales efforts in first- and second-tier cities. In addition, Nissin Foods operates business in other regions including Vietnam, Taiwan, Korea and Australia markets.Nissin Foods is currently a constituent of five Hang Seng Indexes, namely: Hang Seng Composite Index, Hang Seng Composite SmallCap Index, Hang Seng Composite Industry Index - Consumer Staples, Hang Seng SCHK Consumption Index and Hang Seng SCHK Consumer Staples Index. Nissin Foods is eligible for trading under Shanghai-Hong Kong and Shenzhen-Hong Kong Stock Connect. For more information, please visit www.nissingroup.com.hk. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

丹麥比隆, 2026年5月13日 - (亞太商訊 via SeaPRwire.com) - 在樂高基金會的年度會議上，董事會選舉阿格妮特·柯克·克里斯蒂安森為董事會主席。作為樂高集團所有者柯克·克里斯蒂安森家族的第四代成員，她成為該基金會自1986年成立以來僅有的第五位主席。阿格妮特·柯克·克里斯蒂安森自2023年起擔任樂高基金會副主席，接替其兄長托馬斯·柯克·克里斯蒂安森的職務；托馬斯則卸任主席一職，轉任副主席。除在樂高基金會的職務外，阿格妮特·柯克·克里斯蒂安森同時擔任家族控股與投資公司KIRKBI A/S的副主席，該公司持有樂高集團75%的股權。身為新任主席，阿格妮特·柯克·克里斯蒂安森強調樂高基金會在為全球兒童打造更美好未來所扮演的角色：· 「能接任樂高基金會主席一職，並延續我們為兒童所做的這項重要工作，我深感榮幸。自四十多年前成立以來，該基金會在我們家族中始終佔有非常特殊的地位。為兒童創造積極改變的深切責任感，始終流淌在我們家族的血液中，我堅信每個孩子都應有茁壯成長的機會。我為能為這項使命貢獻心力並協助推動其發展而感到自豪。此次主席交接發生在阿格妮特接任非營利基金會「奧勒·柯克基金會」（Ole Kirk's Fond）主席職務的隔年。隨著此次交接，擁有者家族的第四代正進一步擴大其參與度，並對積極所有權展現更堅定的承諾。卸任主席托馬斯·柯克·克里斯蒂安森表示：· 過去10年能擔任樂高基金會主席是我的榮幸，如今能將這個職位交棒給阿格妮特，我感到非常高興。她對樂高基金會的使命深具熱忱，我相信她必將竭盡全力，為「為所有人守護童年」這項事業持續奮鬥。「在擔任副主席期間，她對奠定基金會現行策略發揮了關鍵作用；隨著她接任主席一職，我們將進一步擴大家族在樂高生態系統中的積極所有權與參與度。」托馬斯·柯克·克里斯蒂安森自2016年起擔任樂高基金會主席，在此期間，基金會透過全球合作夥伴組織承諾撥款超過150億丹麥克朗（20億歐元），致力改善兒童發展成果。· 「40年來，樂高基金會始終致力於回饋社會，為兒童打造更美好的世界。我們深知家庭與社區對我們的信任，這份責任絕非兒戲。即使在最艱困的環境中，基金會也能讓孩子展露笑顏、激勵各能力層級的學習者，並改變他們的人生軌跡。我們將以最細膩的關懷與最嚴謹的態度履行這項使命，」阿格妮特·柯克·克里斯蒂安森表示。樂高基金會除了作為樂高集團的股東之一，致力保障集團的持續發展與成功外，亦透過資助並與 Brac、國際救援委員會（IRC）、聯合國兒童基金會（UNICEF）、救助兒童會、挪威難民理事會等組織緊密合作，實踐其慈善使命，支持教育、研究及兒童發展領域的各項計畫。樂高基金會董事會的進一步變動除了阿格妮特與托馬斯·柯克·克里斯蒂安森分別接任主席與副主席職務外，樂高基金會董事會亦於五月會議中選舉英格麗德·斯坦格（Ingrid Stange）為董事會成員，她將帶來在慈善、教育及非營利組織領導方面的豐富經驗。此外，樂高集團前執行長約根·維格·克努德斯托普（Jørgen Vig Knudstorp）與國際紅十字與紅新月會聯合會前秘書長埃爾·哈吉·阿馬杜·蓋耶·西（El Hadji Amadou Gueye Sy，簡稱As），分別在樂高基金會服務十六年與四年後，已離開董事會。托馬斯·柯克·克里斯蒂安森（Thomas Kirk Kristiansen）對這兩位離任董事長期以來對基金會的奉獻表示感謝：· 我們非常期待歡迎英格麗德加入，她將為董事會帶來極具互補性的專業知識。同時，我感謝阿斯（As）提供了無價的見解與經驗，協助塑造我們的工作方向。· 我亦要向約爾根表達最誠摯的謝意，感謝他對基金會的堅定奉獻。在任職期間，約爾根不僅在確立我們的願景與策略方面發揮關鍵作用，更始終未曾忘記我們所服務的兒童。此外，自2021年起擔任董事會成員的瑪露·阿蒙德，接任基金會第二副主席一職。個人簡介：阿格妮特·柯克·克里斯蒂安森樂高基金會2026年 — 董事會主席2023年至2026年 — 董事會第二副主席2008年起 — 董事會成員KIRKBI A/S2024年 — 董事會副主席ADHD+中心，丹麥奧胡斯創辦人奧勒·柯克基金會2025年 - 董事會主席學歷2010年 奧胡斯大學 心理學現任及過往其他職務：· KIRK83 Holding ApS 執行經理· Ruca 諮詢委員會成員· 樂高家族第四代代表· 在家族企業、長期管理及董事會工作方面擁有豐富經驗樂高基金會董事會阿格妮特·柯克·克里斯蒂安森 - 主席托馬斯·柯克·克里斯蒂安森 - 第一副主席瑪盧·阿蒙德 - 第二副主席希拉里·彭寧頓 - 董事英格麗德·斯坦格 - 董事樂高基金會董事會主席1986 - 1993：戈特弗雷德·柯克·克里斯蒂安森（樂高第二代所有者）1993 - 2000：本特·斯科夫2000 - 2016：凱爾德·柯克·克里斯蒂安森（樂高第三代所有者）2016 - 2026：托馬斯·柯克·克里斯蒂安森（樂高第四代所有者）2026 - 阿格妮特·柯克·克里斯蒂安森（樂高第四代所有者）關於樂高基金會：樂高基金會是一家丹麥企業基金會，受託持有樂高集團 25% 的股權。該基金會與全球夥伴攜手合作，致力於滿足兒童需求並捍衛童年的尊嚴。透過慈善捐贈與影響力投資，本基金會致力於為世界各地的每一個孩子營造茁壯成長的條件與空間。更多關於樂高基金會的資訊，請參閱：https://www.legofoundation.com/聯絡資訊：馬德斯·赫維特·格蘭德mads.hvitved.grand@legofoundation.com 消息來源：樂高基金會 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

 財務撮要截至2026年3月31日止三個月(百萬港元)20262025變動收入 1,115.61,071.9+ 4.1%毛利402.1376.1+ 6.9%毛利率36.0%35.1%+ 0.9個百分點本公司擁有人應佔溢利122.4110.0+ 11.3%純利率11.0%10.3%+ 0.7個百分點經調整EBITDA209.0201.5+ 3.7%每股盈利（港仙）11.7310.54+ 11.3%香港, 2026年5月13日 - (亞太商訊 via SeaPRwire.com) - 日清食品有限公司（「日清食品」或「公司」，連同其附屬公司統稱「集團」；股份代號：1475）今天公布截至2026年3月31日止三個月（「報告期」）之未經審核第一季度財務業績。報告期內，集團錄得收入1,115.6百萬港元，較2025年同期的1,071.9百萬港元增加4.1%。毛利按年上升6.9%至402.1百萬港元，主要由於持續實施成本效益措施所致。毛利率由2025年同期的35.1%增加0.9個百分點至36.0%，主要由於核心品牌銷量增加，消化了成本壓力。本公司擁有人應佔溢利錄得122.4百萬港元，按年顯著上升11.3%；經調整EBITDA則按年增長3.7%至209.0百萬港元。來自香港及其他地區業務的收入增加3.1%，此乃由於麵類業務表現穩健，特別是集團核心品牌合味道及出前一丁。內地業務收入增加4.6%，主要受惠於內陸地區的銷售擴大及人民幣兌港元升值所致。日清食品執行董事、董事長兼首席執行官安藤清隆先生表示：「延續2025年建立的良好增長勢頭，集團於本季度持續錄得穩健的業務表現，主要市場的營運表現保持平穩。收入及盈利按年有所提升，主要受穩定的銷售量所支持。核心即食麵業務於各地區持續表現理想，而高端化及多元化策略亦於中國內地進一步取得成效。憑藉均衡的地域布局及持續提升的營運執行力，集團有信心為股東創造可持續的長遠價值。」有關日清食品有限公司日清食品有限公司（「日清食品」，連同其附屬公司統稱「集團」；股份代號：1475）為一間在中國内地及香港知名的食品公司，主要專營優質即食麵市場，旗下眾多品牌不僅知名度高，且廣受顧客喜愛。集團於1984年正式於香港設立營業據點並為香港最大的即食麵公司。集團主要生產及銷售兩個核心企業品牌「日清」及「公仔」，以及多元化的家庭食品品牌組合，出品具標誌性和優質的即食麵、優質冷凍食品（包括冷凍點心及冷凍麵條）並銷售和分銷其他食品及飲料產品（包括蒸煮袋裝產品、零食、礦泉水、醬料及蔬菜產品）。集團五個旗艦品牌「合味道」、「出前一丁」、「公仔麵」、「公仔點心」及「福」在香港亦是其各自食品類別中最受歡迎的選擇。中國内地市場方面，集團以創新技術推出「ECO杯」概念，銷售活動主要集中在中國内地的一線及二線城市。此外，日清食品在其他地區開展業務，包括越南、台灣、韓國及澳洲市場。日清食品被納入5項恒生指數，包括恒生綜合指數、恒生綜合小型股指數、恒生綜合行業指數-必需性消費、恒生港股通消費行業指數和恒生港股通食品飲料消費指數。日清食品現可通過滬港通及深港通下港股通進行交易。詳情請瀏覽www.nissingroup.com.hk。 Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, May 13, 2026 - (ACN Newswire via SeaPRwire.com) - SinoMab BioScience Limited (“SinoMab” or the “Company”, together with its subsidiaries, the “Group”; stock code: 03681.HK) is pleased to announce that Dr. Shui On Leung, Executive Director, Chairman and Chief Executive Officer of the Company, was invited as a special guest to present at the 2026 LifeArc Translational Science Summit in London,UK. As one of the most influential global events in translational medicine, the summit brought together top scientists, practicing clinicians, industry leaders, policymakers and institutional investors from across the globe. During the event, Dr. Shui On Leung delivered a keynote speech, systematically outlining SinoMab’s R&D strategies for autoimmune diseases and the latest clinical progress of its core pipeline, while engaging in in-depth dialogues with international peers.Hosted by LifeArc, a prestigious UK medical research charity, the annual summit is committed to bridging early-stage scientific research and real-world clinical application, with profound expertise and influence in addressing rare diseases and wide-ranging unmet medical needs. This year’s summit centered on how translational research can accelerate the entire journey from laboratory discoveries to patient access, by advancing novel treatment modalities, transforming clinical practice, shaping health policies and driving commercial innovation. Attendees held interdisciplinary discussions on cutting-edge areas including antibody drugs, gene therapy and cell therapy, exploring solutions to break through core bottlenecks in translational medicine and boost integrated development across industry, academia, research and clinical sectors. Dr. Shui On Leung’s invitation to this high-profile event marks high recognition from leading international authorities of SinoMab’s innovative efforts in immunotherapy.In his keynote address, Dr. Shui On Leung analyzed the current landscape and prevailing challenges in global R&D for autoimmune disease therapeutics, and elaborated on SinoMab’s differentiated innovation framework anchored in “First-in-Class” and “Best-in-Class” drug development. He gave a detailed introduction to SM17, the Company’s flagship humanized monoclonal antibody targeting the interleukin-25 (IL-25) receptor. By precisely binding to IL-25 receptor, a key upstream alarmin molecule regulating type 2 immune responses, SM17 blocks inflammatory cascade reactions at the source. It holds broad therapeutic potential for a spectrum of inflammatory and immune-mediated disorders, including atopic dermatitis (AD), inflammatory bowel disease (IBD), asthma, chronic rhinosinusitis with nasal polyps, and idiopathic pulmonary fibrosis. Dr. Leung shared a series of landmark milestones achieved by SM17 recently. In the AD treatment landscape, Phase 1b clinical data demonstrated outstanding therapeutic efficacy. In the high-dose cohort, 91.7% of patients reported significant itch relief measured by the NRS-4 scale, 75% achieved EASI 75 skin lesion improvement, and 41.7% attained complete or near-complete clearance of AD symptoms (IGA 0/1). Such clinical outcomes outperform existing IL-4/IL-13 targeted monoclonal antibodies, while the product also boasts a more favorable safety profile compared with JAK inhibitors. Building on these promising results, the Phase II clinical trial of SM17 for moderate-to-severe AD completed first patient dosing in mainland China on 31 March 2026. The trial plans to enroll approximately 210 participants, with full enrollment expected in the second half of 2026 and topline clinical data slated for release in the first half of 2027. In terms of administration convenience, the Phase I bridging study of SM17 subcutaneous formulation released positive topline results on 25 March 2026. Data from 30 healthy volunteers confirmed the subcutaneous injection route with satisfactory safety and stable pharmacokinetic performance. Only one mild Grade 1 injection site rash was reported, which resolved spontaneously without intervention, and robust absolute bioavailability was validated, laying a solid foundation for the development of more user-friendly subcutaneous dosing regimens. Furthermore, SM17 has successfully expanded its therapeutic indications to IBD. Its Investigational New Drug (IND) application for Crohn’s disease and ulcerative colitis was officially approved by China’s National Medical Products Administration (NMPA) on 24 February 2026. Relevant bridging studies were finalized in the same month, paving the way for direct progression to Phase II clinical development. Dr. Leung also highlighted the Company’s innovative early-stage pipeline, including the anti-CGC antibody (a first-in-class humanized anti-γc antibody), which has demonstrated potential in the treatment of autoimmune diseases such as alopecia areata and vitiligo, with an IND submission planned for the fourth quarter of 2026. A novel bispecific antibody targeting RANKL and sclerostin has demonstrated superior efficacy over marketed therapies in preclinical studies for bone-related disorders, and its IND filing is targeted for the first half of 2027. Dr. Leung emphasized that by focusing on innovative and untapped drug targets, SinoMab has built a synergistic product portfolio, striving to deliver safer, more effective and more accessible breakthrough therapies for patients worldwide.Being invited to this LifeArc Translational Science Summit is not only a strong recognition from a respected international institution of SinoMab’s innovative edge and exploratory work in antibody R&D, but also a key opportunity to deepen our global partnerships. Through in-depth exchanges with leading scientists, clinical researchers and senior executives of multinational pharmaceutical companies, SinoMab has further expanded its international academic network and potential partnership channels, laying a solid foundation for future technology in-licensing, co-development, out-licensing and commercialization. Dr. Shui On Leung stated that the Company will remains focused on addressing unmet clinical needs in autoimmune diseases. It will accelerate global multi-center clinical development of core pipeline assets such as SM17, while actively exploring how AI and other new technologies can boost novel target discovery. In addition, drawing on strategic collaborations with institutions like the Sun Yat-sen University Institute of Advanced Studies Hong Kong, SinoMab aims to strengthen its translational capabilities from bench to bedside. Looking ahead, SinoMab will seize the rapid growth opportunities in China’s biotech out-licensing market, stay true to a differentiated global innovation path, and actively pursue diversified collaboration models with global partners, and accelerate the delivery of innovative therapies to patients worldwide, while creating long-term value for shareholders.About SinoMab BioScience LimitedSinoMab BioScience Limited (Stock Code: 03681.HK) is a pioneer in the research and development of first-in-class and potential best-in-class therapeutic antibody drugs, focusing on autoimmune diseases, neurodegenerative disorders, and other debilitating diseases, committed to addressing unmet medical needs. SinoMab has consistently focused on developing therapeutic antibodies targeting novel targets and employing innovative mechanisms, aiming to achieve differentiated clinical outcomes in areas where existing therapies have shown limited efficacy. Its rich R&D pipeline includes: SM17, which has demonstrated exceptional anti-pruritic effects, skin clearance rates, and safety profiles in the treatment of AD, with potential applications in asthma and idiopathic pulmonary fibrosis (IPF); its flagship anti-CD22 antibody, Suciraslimab , which has been clinically validated for efficacy in rheumatoid arthritis (RA) and is currently undergoing clinical evaluation for systemic lupus erythematosus (SLE) and Alzheimer's disease; another innovative anti-CGC (common gamma chain) monoclonal antibody, which is preparing to enter clinical studies for the treatment of alopecia areata and vitiligo; and a bispecific monoclonal antibody developed by SinoMab that simultaneously stimulates bone growth and inhibits bone loss for the treatment of osteoporosis. With breakthrough efficacy as its core pursuit, SinoMab continuously redefines patient care standards and maintains a leading position in the field of breakthrough therapies.  This press release is issued by Zhenzhuo Group on behalf of SinoMab BioScience Limited.Investor and Media InquiriesContact Person: Bunny LeeNomia ZhouQiuyan DengPhone: (852) 5316 9995Email: ir_sinomab@zhenzhuoglobal.com Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Anson Resources and POSCO Holdings have received board approval for a binding agreement to develop POSCO's Direct Lithium Extraction ("DLE") Demonstration Plant at the Green River Lithium Project in Utah.POSCO to lead the project at its own expense including the design, construction and operation of its proprietary Direct Lithium Extraction ("DLE") Demonstration PlantPOSCO to pay ~AUD $7.2 million (USD $5.2 million) non-dilutive facilitation fee to Anson.The collaboration positions Green River as a potential cornerstone asset in the emerging U.S. critical minerals and battery supply chain.During operation of the demonstration plant, the parties will evaluate broader commercial opportunities, including potential future joint investment and strategic cooperation.NEWPORT BEACH, CA, May 13, 2026 - (ACN Newswire via SeaPRwire.com) - Anson Resources Limited (ASX:ASN) ("Anson" or the "Company") is pleased to announce that both POSCO Holdings Inc. ("POSCO")'s board and the Company's board have approved the terms for a definitive Demonstration Plant Agreement ("Agreement") relating to the construction and operation of a Direct Lithium Extraction ("DLE") demonstration facility at the Green River Lithium Project in the Paradox Basin, Utah, USA.The board approvals mark a significant progression from the previously announced Memorandum of Understanding (see ASX Announcement 30 June 2025), establishing a framework under which POSCO will operate its own non-commercial DLE demonstration plant designed to validate lithium extraction at continuous industrial scale.Under the agreement POSCO committed to setting up its DLE demo-plant to extract lithium from brines produced from the Bosydaba #1 well owned by Anson at the Green River Lithium Project. POSCO will be responsible for engineering, construction, operation and maintenance of the facility, while Anson will provide access to property, infrastructure and brine supply. POSCO will pay Anson a non-dilutive facilitation fee of AUD ~$7.2 million (USD $5.2 million).The definitive agreement is expected to be signed before the end of Q2 2026. POSCO is expected to commence operation of the demonstration plant in 2027 and complete the work in 2028.The two companies will continue to explore potential business cooperation opportunities, including joint investment in the Project, during the operation of the demonstration plant, as outlined in the MoU Agreement, see ASX Announcement 30 June 2025.Strategic ImportanceDemonstrates strong industry validation of Green River's low-cost lithium potential.Accelerates technical de-risking through continuous demonstration-scale testing.Positions Green River as a key participant in the emerging U.S. domestic battery materials supply chain.Executive CommentaryExecutive Chairman & CEO, Mr. Bruce Richardson commented:"Securing a definitive agreement with POSCO represents a transformational step forward for the Green River Lithium Project.Moving from a non-binding MoU to a fully executed agreement underscores the strong technical confidence POSCO has in our asset and highlights the increasing strategic importance of domestic U.S. lithium supply."POSCO Holdings commented:"With the approval of the terms for a binding agreement, POSCO Holdings will advance validation of DLE technology in the United States and evaluate commercialisation pathways for future lithium production.We believe collaboration with Anson Resources at Green River will contribute to strengthening the North American lithium supply chain."Key Elements of the Definitive AgreementItemKey TermsProjectNon-commercial DLE Demonstration Plant - Green River Lithium ProjectResponsibilityPOSCO to bear cost for the design, construction, operations and maintenance for Demonstration PlantFacilitation FeeUSD $5.2MTermTo December 2028Brine SupplyProvided from Bosydaba #1 well with defined performance targetsAbout POSCO HoldingsPOSCO Holdings Inc. is a leading South Korean industrial group with strategic investments across steel, energy, and battery materials. POSCO Group is developing a global supply chain to support the transition EV and has invested in a total of 93,000 tonnes of lithium production annually in Argentina and South Korea. The company has made significant investments in both brine and hard-rock lithium resources across South America and Australia and is advancing proprietary Direct Lithium Extraction (DLE) technologies to accelerate low-carbon lithium production.This announcement has been authorized for release by the Executive Chairman and POSCO Holdings.For further information please contact:Bruce Richardson Will MazeExecutive Chairman and CEO Head of Investor RelationsE: info@Ansonresources.com E: investors@Ansonresources.comPh: +61 7 3132 7990 Ph: +61 7 3132 7990www.Ansonresources.com Follow us on Twitter @Anson_irSOURCE: Anson Resources Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, May 12, 2026 - (ACN Newswire via SeaPRwire.com) - Anytime Fitness (the “Company”), a globally renowned 24-hour fitness chain, has seen strong growth across the Asia-Pacific region in recent years. Benefiting from a significant rise in public health awareness in the post-pandemic era, it has continued to accelerate its market expansion. In particular, Hong Kong, as a strategic growth market for the Company, is expected to reach the milestone of 50 clubs by the end of the year. A further 25 clubs have already secured funding, with potential to open an additional 30 to 40 clubs over the next few years. Meanwhile, the Company projects that its total number of clubs across the Asia-Pacific region will reach 2,500 to 3,000 over the next two to three years, underscoring its long-term commitment to and confidence in the regional market.A Truly Global Brand, Powered by Regional ExpertiseAnytime Fitness operates as a truly global brand, with a presence across 42 countries and territories on all seven continents, offering members seamless access to clubs worldwide. Unlike competitors that are merely international, Anytime Fitness delivers a globally connected fitness ecosystem, combining scale, consistency, and member-centric innovation.In Asia-Pacific, growth is led by Inspire Brands Asia (“IBA”), the master franchisee for Anytime Fitness across key markets including Hong Kong, Singapore, Thailand, the Philippines, Indonesia, Vietnam, Taiwan, and Malaysia. This structure enables strong regional execution while maintaining global brand standards.Community-Based Approach: Replicating Singapore’s Success in Hong KongThe core philosophy of Anytime Fitness is to bring fitness services into the community and provide a convenient, stress-free workout experience — a model that has proven successful worldwide. Ryan Cheal, Group Chief Operating Officer of IBA, said: “As a highly mature market in the region, we’ve sold around 200 franchises and operate more than 160 clubs in Singapore. Its market penetration and consumer patterns have provided a clear blueprint for our expansion in Hong Kong. With a similar market profile but a larger population base, Hong Kong offers substantial potential for community-based development. We are confident that we can replicate the success achieved in Singapore, and expect that once Hong Kong surpasses the critical milestone of 50 clubs, network effects will drive even faster growth.”Franchising Drives Scalable Expansion with End-to-End Support for PartnersIn terms of its operating model, Anytime Fitness operates a hybrid model of corporate-owned and franchised clubs. Currently, around 50% of clubs in Hong Kong are corporate-owned, enabling the brand to gain deep insights into the local market and provide more effective support to franchise partners. In contrast, the proportion of corporate-owned clubs in Singapore stands at around 20%. This structure ensures that the Company can maintain high service standards and brand consistency while expanding rapidly.The Company’s franchise ecosystem offers end-to-end support, including:- Site selection and club development; - Equipment and operational setup; - Marketing and member acquisition; - Training and business coaching for franchise partners. This integrated approach ensures consistency in member experience while enabling rapid and sustainable expansion. At present, around 80% of new clubs are opened by existing franchisees. Investors from sectors such as retail and F&B are also increasingly shifting their investments towards the health industry, demonstrating the model’s strong appeal and the market’s recognition of its growth potential.Tech-Powered Member Experience: Building a Comprehensive Health EcosystemIn response to the trend of intelligent transformation, Anytime Fitness is actively leveraging technology to enhance service value. To enhance member experience, Anytime Fitness continues to invest in technology and personalised wellness solutions. Its next-generation member app integrates:- Personalised training plans; - Class and trainer bookings;- Recovery guidance and nutrition support.The ecosystem is further supported by tools such as Evolt, a body composition analysis system capable of measuring over 40 biometric indicators, giving members deeper insight into their health and fitness progress. Currently, the app’s average daily member usage rate is around 30% to 35%, effectively strengthening user engagement and retention.Understanding the Hong Kong Member: Strength, Wellness, and LifestyleRecent member insights highlight evolving fitness priorities in Hong Kong:- 57% of members (3 in 5) prioritise strength training; - 16% (1 in 6) are driven by broader wellness goals, including mental health and overall lifestyle improvement. These trends reflect a structural shift in consumer behaviour, where fitness is no longer discretionary, but an essential part of modern living.Focusing on “Essential Health Needs” and “Human-Centered Connection”, with a Stable and Positive Industry OutlookDespite the complex macroeconomic environment, the Company remains optimistic about the outlook for the industry. Ryan noted that the fitness population is continuing to grow, with participation among seniors steadily increasing and health awareness rising. Consumer spending priorities are also undergoing a structural shift, with health and fitness having evolved from “discretionary spending” to “essential lifestyle”. Notably, younger demographics have shown a particularly strong willingness to invest in health, wellness, and longevity, providing the industry with resilience that transcends economic cycles.Looking ahead, Anytime Fitness will continue to innovate its products and services. It launched a new club design last month, enhancing the strength training and exercise recovery areas, and plans to further improve its nutrition guidance services next year. Ryan concluded, “In this technology-driven era, the Company will continue to uphold the core value of ‘human-centered connection’, using convenient, friendly, and professional services to help more people establish consistent exercise habits and embrace a healthier lifestyle. We are confident in the Asia-Pacific and Hong Kong markets and believe that future growth will be even faster and more innovative.”About Anytime FitnessAnytime Fitness is the largest and fastest-growing global fitness brands in the world, averaging 300 new clubs per year while serving over 5 million members at nearly 6,000 clubs in 42 countries and territories on all seven continents. Open 24-hours a day, 365 days a year, Anytime Fitness delivers personalized and affordable health and wellness training, coaching, nutrition, and recovery guidance for our members—in the club, in their homes, in their pockets, wherever they are and anytime they need it. All franchised clubs are individually owned and operated, and members have access to any Anytime Fitness club worldwide.For more information, please visit：https://www.anytimefitness.com/.Media Inquiries:Inspire Brand AsiaJerry Chow Email: Jerry.chow@inspirebrandsasia.com  Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

TAMPA, FLA., May 12, 2026 - (ACN Newswire via SeaPRwire.com) - The Global Technology Distribution Council (GTDC), the world's largest consortium of technology distributors, named V.S. Hariharan, Managing Director and Group CEO of Redington Limited, to its Executive Committee. The committee provides operational oversight and helps guide GTDC's long-term strategy, advancing the organization's mission to strengthen distribution's role in the global technology marketplace."Hari is a respected global IT leader and a strong advocate for distribution," said Frank Vitagliano, CEO of GTDC. "He brings valuable insight to our leadership team and will help shape our long-term strategy and initiatives that highlight the expanding role of distributors in today's technology ecosystem."GTDC's executive leadership group oversees the organization's vision, develops and updates its strategic plans and advocates for its members' common interests. Comprised of senior executives from member distributors, the EC carries out the non-profit association's mission to educate, advocate and influence the tech community on the evolving role of IT distributors. Council leaders also sponsor and oversee GTDC research, the association's three regional executive level events and other member driven initiatives. Hariharan will support these efforts, strengthening partnerships between distributors and vendors and reinforcing distribution's value across the global technology marketplace."Delivering innovative solutions that meet the evolving needs of the technology community has been my core focus at Redington, and I look forward to working with other distribution leaders to serve GTDC in a similar capacity," said Hariharan. "As a Technology Orchestrator, we are focused on connecting partners, platforms and possibilities to unlock next opportunities across markets. I see this role as a natural extension of that commitment, and look forward to strengthening collaboration, sharpening our view of global industry trends, and helping the ecosystem navigate the opportunities and challenges ahead."Hariharan is the Managing Director and Group CEO of Redington, an $11.8 billion distribution and supply chain solutions provider, where he leads operations across 40 markets. A seasoned industry leader, he brings over 35 years of experience across sales, marketing, and general management, including senior leadership roles at Hewlett Packard and Wipro Infotech, along with entrepreneurial experience in scaling solar solutions for off grid markets.Under his leadership, Redington is accelerating its role as a Technology Orchestrator, bringing together OEMs and partnersQ to drive innovation, agility, and growth across emerging markets.About the GTDCThe Global Technology Distribution Council is the industry consortium representing the world's leading technology distributors. GTDC members drive an estimated $180 billion in annual worldwide sales of products, services and solutions through diverse business channels. GTDC conferences foster strategic supply-chain partnerships that address the fast-changing needs of vendors, end customers and distributors. Members include AB S.A, Arrow Electronics, CMS Distribution, Computer Gross Italia S.p.A., D&H Distributing, ELKO Group, Esprinet S.p.A., Exclusive Networks, Exertis, Infinigate, Ingram Micro, Intcomex, Logicom Public Limited, Mindware, Nexora, Redington Limited, SiS Technologies, Tarsus Distribution, TD SYNNEX, TIM AG and Westcon-Comstor.Brian ShermanCommCentric Solutions (on behalf of GTDC)814-882-4432bsherman@commcentric.comSOURCE: Global Technology Distribution Council Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Brisbane, Queensland, Australia--(ACN Newswire via SeaPRwire.com - May 12, 2026) - Graphene Manufacturing Group Ltd (TSXV: GMG) (OTCQX: GMGMF) ("GMG" or the "Company") is pleased to announce that the Company has signed a 3 year lease, with options for term extension, to support production expansion and to provide additional office space for staff. The site is within the Richlands suburb of Brisbane, nearby to the existing headquarters of the Company. The site has over 2,100 square metres of covered space — including offices, meeting rooms and a high ceiling warehouse.Craig Nicol, CEO & Managing Director of the Company, commented "This is the first site for expansion for our company — for both staff and production assets. We will look to expand our production assets here after the Gen 2 Project is completed — which is expected at the end of June 2026."Jack Perkowski, Non-Executive Chairman and Director of the Company, commented: "As we look to expand our production plants around the world — this is the first significant step in our global growth plan."Operations UpdateGMG is focused on delivering its Gen 2.0 Graphene Production Project (the "Gen 2.0 Project") by end of June 2026 — which is expected to produce at least 10 tonnes per annum of graphene at its headquarters in Richlands, Queensland, Australia.Once the Gen 2.0 Project is commissioned and operating, GMG plans to replicate and establish other production plants around the world to enable scaled production for potential sales, diversify and lower production risks, and reduce operating costs by locating the plant in countries with lower operating costs, including low cost natural gas — one of GMG's key production input costs.Currently, GMG is planning three potential expansion projects — two in North America (potentially one in US and one in Canada) in addition to an expansion production project in Australia (located on the expansion lease outlined in this release). GMG proposes to mature these projects and expand production in line with sales for all of its products.The expansion program for GMG includes the following 5 production plants:Graphene Production (from natural gas)Coating Blend Plant (for the graphene coating THERMAL-XR®)Lubricant Blend Plant (for the graphene lubricant additive G® LUBRICANT)Graphene Slurry Plant (for the SUPA G Lithium-Ion Battery Additive)Battery Assembly Plant (for the Graphene Aluminium Ion Battery)Figure 1To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8082/297118_53e7bb85547cbaac_001full.jpgAbout GMG:GMG is an Australian based clean-technology company which develops, makes and sells energy saving and energy storage solutions, enabled by graphene manufactured via in house production process. GMG uses its own proprietary production process to decompose natural gas (i.e. methane) into its natural elements, carbon (as graphene), hydrogen and some residual hydrocarbon gases. This process produces high quality, low cost, scalable, 'tuneable' and low/no contaminant graphene suitable for use in clean-technology and other applications.The Company's present focus is to de-risk and develop commercial scale-up capabilities, and secure market applications. In the energy savings segment, GMG has initially focused on graphene enhanced heating, ventilation and air conditioning ("HVAC-R") coating (or energy-saving coating) which is now being marketed into other applications including electronic heat sinks, industrial process plants and data centres. Another product GMG has developed is the graphene lubricant additive focused on saving liquid fuels initially for diesel engines.In the energy storage segment, GMG and the University of Queensland are working collaboratively with financial support from the Australian Government to progress R&D and commercialization of graphene aluminium-ion batteries ("G+AI Batteries"). GMG has also developed a graphene additive slurry that is aimed at improving the performance of lithium-ion batteries.GMG's 4 critical business objectives are:Produce Graphene and improve/scale cell production processesBuild Revenue from Energy Savings ProductsDevelop Next-Generation BatteryDevelop Supply Chain, Partners & Project Execution CapabilityFor further information please contact:Craig Nicol, Chief Executive Officer & Managing Director of the Company at craig.nicol@graphenemg.com, +61 415 445 223Leo Karabelas at Focus Communications Investor Relations, leo@fcir.ca, +1 647 689 6041Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accept responsibility for the adequacy or accuracy of this news release.Cautionary Note Regarding Forward-Looking StatementsThis news release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian and U.S. securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as "intends", "believes" "expects" or "anticipates", or variations of such words and phrases or statements that certain actions, events or results "may", "could", "should", "would" or will "potentially" or "likely" occur. This information and these statements, referred to herein as "forward‐looking statements", are not historical facts, are made as of the date of this news release and include without limitation, statements as to GMG's focus on, and the timing and production expectations of, the Gen 2 Project, intentions regarding the number, purpose and location of expansion projects, intentions to de-risk, reduce operating costs and develop commercial scale-up capabilities, GMG's focus in the energy savings segment, GMG's intentions for the use of graphene lubricant additive on saving liquid fuels, expectations for R&D and commercialization of G+AI Batteries, GMG's ability to improve the performance of lithium-ion batteries and GMG's critical business objectives.Such forward-looking statements are based on a number of assumptions of management, including the patent and potential market size of G® LUBRICANT. Additionally, forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of GMG to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation that GMG does not receive or receive on a timely basis the fully signed consent notice from the and the risk factors set out under the heading "Risk Factors" in the Company's annual information form dated November 4, 2025 available for review on the Company's profile at www.sedarplus.ca.Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial out-look that are incorporated by reference herein, except in accordance with applicable securities laws.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/297118 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

CALGARY, AB AND VANCOUVER, BC / ACN Newswire via SeaPRwire.com / May 12, 2026 / CANEX Metals Inc. ("CANEX") (TSXV:CANX) and Gold Basin Resources Corporation ("Gold Basin") (TSXV:GXX) are pleased to announce that they have entered into a definitive agreement (the "Arrangement Agreement") to combine their respective businesses by way of a plan of arrangement under the Business Corporations Act (British Columbia) (the "Arrangement"). The combined company will be managed by the CANEX executive team.Under the terms of the Arrangement, shareholders of Gold Basin ("Gold Basin Shareholders") will receive 0.592 shares of CANEX ("CANEX Shares") per share of Gold Basin ("Shares") held, the same consideration received by Gold Basin Shareholders who tendered to the CANEX offer to acquire Shares which expired on February 10, 2026. This represents a premium of 242.0% to the last trading price of the Shares prior to the Cease Trade Order, based on the closing price of the CANEX Shares as of May 8, 2026.Dr. Shane Ebert, President and CEO of CANEX stated: "Today's announcement of an agreement to combine the two companies will allow us to consolidate and advance a promising gold district in Arizona. CANEX will be pleased to welcome Gold Basin Shareholders as new shareholders of CANEX."Jordan Ross, independent director and Chair of the Gold Basin Special Committee, commented: "The Arrangement Agreement represents a strategic milestone for our shareholders. By partnering with CANEX, we are unlocking the full potential of our Arizona project while providing a stable, clear-cut path forward that resolves previous liquidity and regulatory challenges. Following a rigorous review with our professional advisors, we are confident this agreement offers the most robust and value-driven future for our investors."Benefits to Gold Basin ShareholdersSignificant Upfront Premium to Shareholders. The consideration offered under the Arrangement represents a 242.0% premium to the last trading price of the Shares prior to the Cease Trade Order, based on the closing price of the CANEX Shares as of May 8, 2026.Consolidation of Gold Districts and Near-Term Exploration and Expansion. The Arrangement will consolidate an advanced oxide gold exploration camp in Mohave County, Arizona hosting multiple zones of gold mineralization with strong drill results across an eight kilometre by eight kilometre area, opening up potential near-term exploration on favourable targets.Diversification. Completing the Arrangement will provide Gold Basin Shareholders not only with exposure to a consolidated gold district in Mohave County, Arizona, but also to CANEX's Louise Project in British Columbia. On July 31, 2025, CANEX announced results from an induced polarization geophysical survey which identified a new and previously unknown chargeability target two kilometres west of the historic Louise deposit and a large steeply dipping zone of high chargeability below and to the north of the historic Louise deposit.Focused, Professional and Cost-Effective Management Team. The Arrangement places the consolidated district under CANEX's highly focused, professional and cost-effective management team, which will provide strong operational and governance oversight.Experienced Board of Directors. Following the Arrangement, the Resulting Issuer's board of directors will be led by experienced industry professionals, comprised of members of the current board of directors of CANEX.Liquidity. The Arrangement will provide Gold Basin Shareholders with a more liquid investment. On May 6, 2025, the British Columbia Securities Commission imposed a Cease Trade Order against the Gold Basin Shares. The next day, the Canadian Investment Regulatory Organization imposed a halt in trading of the Gold Basin Shares on the TSXV. There is no expectation that the Cease Trade Order will be rescinded if the Arrangement were not to proceed and Gold Basin were to continue with the status quo.Enhanced Financial Capacity. CANEX has demonstrated an ability to raise capital and has strong support from a number of high profile industry professionals. With an enhanced capital markets profile, the Resulting Issuer is expected have even better access to lower-cost capital and an increased capability to advance its exploration properties.Going Concern. In the absence of the Arrangement, there is considerable risk that Gold Basin will not have the ability to continue as a going concern and realize its assets and discharge its liabilities in the normal course of business. Currently, Gold Basin has asserted liabilities of over $2 million, no cash or marketable securities and no revenue. Gold Basin's ability to raise equity financing is restricted by the Cease Trade Order.Details of the ArrangementCANEX and Gold Basin entered into a definitive Arrangement Agreement on May 11, 2026, pursuant to which CANEX will acquire all of the issued and outstanding common shares of Gold Basin ("Gold Basin Shares") by way of a statutory plan of arrangement under the Business Corporations Act (British Columbia).Holders of Gold Basin Shares ("Gold Basin Shareholders") will receive 0.592 common shares in the capital of CANEX (the "CANEX Shares", and such ratio being the "Exchange Ratio") in exchange for each Gold Basin Share held immediately prior to the effective time of the Arrangement. Upon completion of the Arrangement, existing holders of CANEX Shares and former Gold Basin Shareholders will own approximately 67.7% and 32.3% of the total issued and outstanding CANEX Shares, respectively, on a fully diluted basis.CANEX expects to issue an aggregate of approximately 38,505,033 CANEX Shares to Gold Basin Shareholders, based on the number of Gold Basin Shares outstanding as at the date of this announcement.The Arrangement is expected to close in June 2026, subject to the receipt of all required court, shareholder, regulatory, and stock exchange approvals. Following completion of the Arrangement, the CANEX Shares will remain listed on the TSXV and the Gold Basin Shares will be delisted from the TSXV.Term LoanConcurrently with the entering into of the Arrangement Agreement, CANEX and Gold Basin have agreed to enter into a senior secured term loan (the "Term Loan") as soon as practicable pursuant to which CANEX will lend up to $900,000 to Gold Basin at an interest rate per annum equal to the Royal Bank of Canada Prime Rate plus 5.0%. The maturity of the Term Loan shall be six months and the Term Loan shall be secured by a first ranking general security agreement over all of Gold Basin's present and after-acquired assets, a first ranking mortgage charge over Gold Basin's split mineral rights and first ranking security agreements encumbering all of Gold Basin's other mineral tenure. The proceeds from the Term Loan will be used by Gold Basin for aged payables, day to day working capital and general corporate expenditures, direct advances paid by CANEX to third party suppliers, service providers and creditors of Gold Basin, and expenses in connection with the Arrangement. The Term Loan is not contingent on the completion of the Arrangement.The Term Loan is subject to the approval of the TSXV. No fees are payable in connection with the Term Loan.Arrangement Conditions and TimingThe Arrangement will be effected by way of a court-approved plan of arrangement under the Business Corporations Act (British Columbia) and will require the approval of: (i) at least 66⅔% of votes cast by Gold Basin Shareholders, and (ii) a simple majority of the votes cast by disinterested Gold Basin Shareholders, excluding for this purpose the votes held by any person specified under Multilateral Instrument 61-101 - Protection of Minority Security Holders in Special Transactions. The Gold Basin Shares held by CANEX will not be excluded from either vote. CANEX currently holds 70,088,199 Gold Basin Shares, representing 51.86% of the issued and outstanding Gold Basin Shares.The Arrangement Agreement includes customary representations and warranties for a transaction of this nature as well as customary interim period covenants regarding the operation of CANEX's and Gold Basin's businesses. The Arrangement Agreement also includes customary deal protections in favour of each of CANEX and Gold Basin. With respect to CANEX, these protections include non-solicitation covenants, and a right to match any superior proposals. With respect to Gold Basin, these protections include a fiduciary-out provision. The Arrangement Agreement includes a termination fee of $211,777 payable by Gold Basin in the event the Arrangement Agreement is terminated in certain circumstances.In addition to securityholder and court approvals, the Arrangement is subject to applicable regulatory approvals, stock exchange approvals and the satisfaction of certain other closing conditions customary in transactions of this nature.None of the securities to be issued pursuant to the Arrangement have been or will be registered under the U.S. Securities Act, or any state securities laws, and any securities issuable in the Arrangement are anticipated to be issued in reliance upon available exemptions from such registration requirements pursuant to Section 3(a)(10) of the U.S. Securities Act and applicable exemptions under state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities.Further details of the Arrangement will be included in a management information circular to be prepared by Gold Basin (the "Gold Basin Circular") that will be delivered to Gold Basin Shareholders in advance of a special meeting of Gold Basin Shareholders (the "Gold Basin Meeting") which is scheduled to be held on June 4, 2026. A copy of the Arrangement Agreement will be made available on CANEX's and Gold Basin's respective SEDAR+ profiles at www.sedarplus.com. The Gold Basin Circular will also be made available on Gold Basin's SEDAR+ profile in advance of the Gold Basin Meeting.Board of Directors' and Special Committee RecommendationBased on the recommendation of a special committee comprised of an independent director of Gold Basin (the "Special Committee") and after consultation with independent external financial and legal advisors, the board of directors of Gold Basin (the "Gold Basin Board") unanimously approved the Arrangement and has determined the Arrangement is in the best interests of Gold Basin, and that the consideration to be received by Gold Basin Shareholders is fair, from a financial point of view, to Gold Basin Shareholders (other than CANEX). The Gold Basin Board unanimously recommends that Gold Basin Shareholders vote in favour of the Arrangement at the Gold Basin Meeting.Stifel Nicolaus Canada Inc. has provided a fairness opinions to the Gold Basin Board and Special Committee in connection with the Arrangement.Voting Support AgreementsEach of Gold Basin's directors and officers support the Arrangement and all who own Shares have entered into customary voting support agreements agreeing to vote their Gold Basin Shares, respectively, in favor of the Arrangement. The voting support agreement may be terminated in certain circumstances, including, without limitation, upon termination of the Arrangement Agreement.About CANEX MetalsCANEX Metals (TSX.V:CANX) is a Canadian junior exploration company and the controlling shareholder of Gold Basin Resources, owning 51.86% of Gold Basin. CANEX is advancing its 100% owned Gold Range Project in Mohave County, Arizona. With several near surface bulk tonnage gold discoveries made to date across a 4 km gold mineralized trend, the Gold Range Project is a compelling early-stage opportunity for investors. Gold Basin Resources holds the adjacent Gold Basin Project which hosts large, mineralized trends containing near surface oxide gold mineralization and has seen over 800 historic and current drill holes into mineralized deposits up to 1.7 kilometres in length.CANEX is also advancing the Louise Copper-Gold Porphyry Project in British Columbia. Louise contains a large historic copper-gold resource that has seen very little deep or lateral exploration, offering investors copper and gold discovery potential. CANEX is led by an experienced management team which has made three notable porphyry and bulk tonnage discoveries in North America and is sponsored by Altius Minerals (TSX: ALS), a large shareholder of the Company.About Gold Basin Resources CorporationGold Basin Resources Corporation holds the Gold Basin Project in Mohave County Arizona. The project hosts large, mineralized trends containing near surface oxide gold mineralization and has seen over 800 historic and current drill holes into mineralized deposits up to 1.7 kilometres in length."Shane Ebert"Shane Ebert, President/Director of CANEX and Gold BasinFor Further Information Contact:Shane Ebert at 1.250.964.2699 orJean Pierre Jutras at 1.403.233.2636Web: http://www.canexmetals.caNeither the TSX Venture Exchange nor its regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.Although information provided by Gold Basin for inclusion in this news release is believed by CANEX to be reliable, CANEX has not independently verified such information and cannot provide any assurance of its accuracy, currency, reliability or completeness. Although information provided by CANEX for inclusion in this news release is believed by Gold Basin to be reliable, Gold Basin has not independently verified such information and cannot provide any assurance of its accuracy, currency, reliability or completeness.Forward-Looking StatementsThis news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", "potential", "risk", "anticipated", "future", or "opportunity" or variations of such words and phrases or stating that certain actions, events or results "may", "can", "shall" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements.In this news release, forward-looking statements relate to, among other things, statements regarding: the proposed acquisition by CANEX of all of the Gold Basin Shares pursuant to the Arrangement and the terms thereof; the benefits of the Arrangement; the receipt of necessary shareholder, court and regulatory approvals for the Arrangement; the anticipated timeline for completing the Arrangement; the Gold Basin Meeting and mailing of the management information circular regarding the same; the Term Loan; the terms and conditions pursuant to which the Arrangement will be completed, if at all; the anticipated benefits of the Arrangement; the anticipated filing of materials on SEDAR+; and continuation of CANEX and delisting of Gold Basin. These forward-looking statements are not guarantees of future results and involve risks and uncertainties that may cause actual results to differ materially from the potential results discussed in the forward-looking statements.In respect of the forward-looking statements, CANEX and Gold Basin have relied on certain assumptions that they believe are reasonable at this time, including assumptions as to the ability of the parties to receive, in a timely manner and on satisfactory terms, the necessary regulatory, court, shareholder, stock exchange and other third party approvals and the ability of the parties to satisfy, in a timely manner, the other conditions to the completion of the Arrangement. This timeline may change for a number of reasons, including unforeseen delays in preparing meeting materials; inability to secure necessary regulatory, court, shareholder, stock exchange or other third-party approvals in the time assumed or the need for additional time to satisfy the other conditions to the completion of the Arrangement. Accordingly, readers should not place undue reliance on the forward-looking statements and information contained in this news release concerning these times.Risks and uncertainties that may cause such differences include but are not limited to: the risk that the Arrangement or the Term Loan may not be completed on a timely basis, if at all; the conditions to the consummation of the Arrangement or the Term Loan may not be satisfied; the risk that the Arrangement or the Term Loan may involve unexpected costs, liabilities or delays; the possibility that legal proceedings may be instituted against CANEX, Gold Basin, and/or others relating to the Arrangement or the Term Loan and the outcome of such proceedings; the possible occurrence of an event, change or other circumstance that could result in termination of the Arrangement Agreement; risks relating to the failure to obtain necessary regulatory, court, shareholder, and stock exchange approvals; other risks inherent in the mining industry. Failure to obtain the requisite approvals, or the failure of the parties to otherwise satisfy the conditions to or complete the Arrangement or Term Loan, may result in the Arrangement or Term Loan not being completed on the proposed terms, or at all. In addition, if the Arrangement or Term Loan are not completed, the announcement of the Arrangement and the Term Loan and the dedication of substantial resources of CANEX and Gold Basin to complete the Arrangement and the Term Loan could have a material adverse impact on each of CANEX's and Gold Basin's share price, its current business relationships and on the current and future operations, financial condition, and prospects of each of CANEX and Gold Basin. CANEX and Gold Basin disclaim any responsibility to update these forward-looking statements, except as required by applicable laws.SOURCE: Gold Basin Resources Corporation Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, May 12, 2026 - (ACN Newswire via SeaPRwire.com) - Recently, Guotai Junan International Holdings Limited (“Guotai Junan International” or “GTJAI”, Stock Code: 1788.HK), a subsidiary of Guotai Haitong Group, successfully assisted the State Bank of Mongolia in completing a US$100 million Reg S bond tap issuance as the sole global coordinator. This issuance is a tap-on of the State Bank (Mongolia) initial US$ 200 million 3-year bond issued in September 2025. Upon completion of this tap issuance, the outstanding size of the bond has increased to US$300 million.The issuer has been assigned a “B1” issuer rating by Moody’s, with a “stable” outlook, aligned with Mongolia’s sovereign rating. This issuance also received formal support letters from the Ministry of Finance of Mongolia and the Central Bank of Mongolia. The tap offering was priced at a yield of 8.5%, representing a significant improvement from the original issuance's level of 8.9%. This not only reflects the solid financial fundamentals of the State Bank (Mongolia), but also signals continuously growing confidence among international investors in Mongolia’s economic prospects.The successful completion of this bond tap issuance marks a significant milestone for the State Bank (Mongolia) in the international capital markets. It also represents another in-depth collaboration between the bank and GTJAI, following the latter’s assistance in the bank’s initial US$200 million 3-year bond issuance in September 2025, demonstrating the high level of mutual trust and long-term rapport between the two parties. Amid a complex and volatile global capital market environment, GTJAI precisely seized the market window and efficiently executed the project. This not only further strengthens the Company’s business presence in facilitating offshore bond financing for issuers outside the Greater China region, but also fully showcases its capabilities in professional pricing, global investor resource integration, and cross-market comprehensive financial services in the global capital markets.About GTJAIGuotai Junan International (Stock Code: 1788.HK), a subsidiary of Guotai Haitong Group, is the market leader and first mover for internationalization of Chinese Securities Company as well as the first Chinese securities broker listed on the Main Board of The Hong Kong Stock Exchange through initial public offering. Based in Hong Kong with subsidiaries in Singapore, Vietnam and Macau, GTJAI’s business covers major markets around the world, offering high-quality and diversified comprehensive financial services for clients' overseas asset allocation. Core business includes wealth management, institutional investor services, corporate finance services, investment management and other business. GTJAI has been assigned “Baa2” and “BBB+” long term issuer rating from Moody and Standard & Poor respectively, as well as an MSCI ESG “AAA” rating, Wind ESG “A” rating and SynTao Green Finance “A” rating in ESG. Additionally, its S&P Global ESG score leads 81% of its global peers. The controlling shareholder, Guotai Haitong Securities (Stock Code: 601211.SH/ 2611.HK), is the comprehensive financial provider with a long-term, sustainable and overall leading position in the China’s capital markets. For more information about GTJAI, please visit https://www.gtjai.com. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年5月12日 - (亞太商訊 via SeaPRwire.com) - 近日，國泰海通集團下屬公司國泰君安國際控股有限公司（「國泰君安國際」，股份代號：1788.HK）作爲獨家全球協調人，圓滿協助蒙古國家銀行（State Bank of Mongolia）完成1億美元Reg S債券增發。本次發行爲蒙古國家銀行2025年9月首次2億美元3年期債券的增發，發行完成後，該期債券存續規模增至3億美元。發行人獲穆迪授予「B1」發行人評級，評級展望「穩定」，與蒙古主權評級一致。本次發行亦獲得蒙古財政部及蒙古中央銀行出具的正式支持函。本次增發定價收益率爲8.5%，較原發行8.9%的水平顯著優化，既體現蒙古國家銀行穩健的財務基本面，也反映國際投資者對蒙古經濟前景的信心持續提升。 本次債券增發順利落地，是蒙古國家銀行在國際資本市場的重要里程碑，亦是國泰君安國際繼2025年9月助力其首次完成2億美元3年期債券後，與該行的再度深度合作，彰顯雙方高度互信與長期默契。面對複雜多變的全球資本市場環境，國泰君安國際精准把握市場窗口、高效完成項目執行，既進一步鞏固了公司服務非大中華區域發行人開展境外債券融資的業務布局，也充分展現了其在全球資本市場的專業定價、全球投資者資源整合及跨市場綜合金融服務能力。關於國泰君安國際國泰海通集團下屬公司國泰君安國際（股票代號：1788.HK），是中國證券公司國際化的先行者和引領者，公司是首家通過IPO於香港聯合交易所主板上市的中資證券公司。國泰君安國際以香港爲業務基地，幷在新加坡、越南和澳門設立子公司，業務覆蓋全球主要市場，爲客戶境外資産配置提供高質量、多元化的綜合性金融服務，核心業務包括財富管理、機構投資者服務、企業融資服務、投資管理等。目前，國泰君安國際已分別獲得穆迪和標準普爾授予「Baa2」及「BBB+」長期發行人評級，MSCI ESG「AAA」評級, Wind ESG「A」評級及商道融綠ESG「A」評級，同時其標普全球ESG評分領先全球81%同業。公司控股股東國泰海通證券（股票代號：601211.SH/2611.HK）爲中國資本市場長期、持續、全面領先的綜合金融服務商。更多關于國泰君安國際的信息請見:https://www.gtjai.com Copyright 2026 亞太商訊 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - May 12, 2026) - Casa Minerals Inc. (TSXV: CASA) (OTCQB: CASXF) (FSE: 0CM) ("CASA" or the "Company") is pleased to report that it has received aggregate gross proceeds of $432,777.30 to date in 2026 through the exercise of 4,453,364 common share purchase warrants (the "Warrants").The Warrants were originally issued pursuant to the Company's private placements completed in April of 2025 and February of 2026. Each Warrant entitled the holder to acquire one common share of the Company upon exercise.Net proceeds will be deployed to advance Casa's 2026 exploration programs at the Congress Gold Mine in Arizona and the Arsenault Copper-Gold-Silver Project in British Columbia, and for general working capital purposes."The continued support from our warrant holders is greatly appreciated," said Farshad Shirvani, President and Chief Executive Officer. "This additional capital meaningfully strengthens our balance sheet as we mobilize for an aggressive 2026 drilling and exploration season across our core projects."​​About Casa Minerals Inc.Casa Minerals Inc. is a mineral exploration company focused on gold, copper, and strategic minerals exploration in North America. The Company holds a 90% interest in the historic Congress Gold Mine in Arizona and is advancing multiple projects in British Columbia, including the Arsenault copper-gold-silver project. Casa's experienced management team is committed to creating shareholder value through the discovery and development of economic mineral deposits. For more information, please visit: www.casaminerals.comON BEHALF OF THE BOARD OF DIRECTORSFarshad Shirvani, M.Sc. GeologyPresident, CEO and DirectorFor more information, please contact:Casa Minerals Inc.Farshad Shirvani, President & CEOPhone: (604) 678-9587Email: contact@casaminerals.comNEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/297081 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com